<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5eb0e4a7-f749-4308-8873-efba1717a0c6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use KEVZARA<sup>Â®</sup> safely and effectively. See full prescribing information for KEVZARA. <br/>
      <br/>KEVZARA (sarilumab) injection, for subcutaneous use<br/> Initial U.S. Approval: 2017 </title>
   <effectiveTime value="20250516"/>
   <setId root="827bc01c-d379-4266-a18c-c7f904b76af3"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="824676584" root="1.3.6.1.4.1.519.1"/>
            <name>Sanofi-Aventis U.S. LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="297730488" root="1.3.6.1.4.1.519.1"/>
                  <name>Sanofi Winthrop Industrie</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="297730488" root="1.3.6.1.4.1.519.1"/>
                        <name>Sanofi Winthrop Industrie</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="313218430" root="1.3.6.1.4.1.519.1"/>
                        <name>Sanofi-Aventis Deutschland GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="945589711" root="1.3.6.1.4.1.519.1"/>
                        <name>Regeneron Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="050424395" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="985127419" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="151663234" root="1.3.6.1.4.1.519.1"/>
                        <name>Nelson Laboratories, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="d16193e8-e470-4945-a4fe-41bdc3462a20"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250516"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5908" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KEVZARA</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sarilumab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="150" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SARILUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SARILUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.94" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="3.71" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.28" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="57" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5908-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5908-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170522"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 3: PREFILLED BIOLOGIC DELIVERY DEVICE/SYSTEM (SYRINGE, PATCH, ETC.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5908-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170522"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 3: PREFILLED BIOLOGIC DELIVERY DEVICE/SYSTEM (SYRINGE, PATCH, ETC.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170522"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5910" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KEVZARA</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sarilumab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SARILUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SARILUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.94" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="3.71" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.28" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="57" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5910-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5910-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170522"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5910-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170522"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170522"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5920" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KEVZARA</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sarilumab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="150" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SARILUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SARILUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.94" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="3.71" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.28" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="57" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5920-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5920-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180413"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5920-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180413"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170522"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5922" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KEVZARA</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sarilumab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SARILUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NU90V55F8I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SARILUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.94" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="3.71" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.28" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="57" unit="mg"/>
                              <denominator value="1.14" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5922-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5922-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180413"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1.14" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5922-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180413"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170522"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="2efd4c0a-6a47-436b-b372-633db9e81d68"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: RISK OF SERIOUS INFECTIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Patients treated with KEVZARA are at increased risk for developing serious infections that may lead to hospitalization or death <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> Opportunistic infections have also been reported in patients receiving KEVZARA. Most patients who developed infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid use of KEVZARA in patients with an active infection.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Reported infections include: </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before KEVZARA use and during therapy. Treatment for latent infection should be initiated prior to KEVZARA use. </content>
                     </item>
                     <item>
                        <content styleCode="bold">Invasive fungal infections, such as candidiasis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. </content>
                     </item>
                     <item>
                        <content styleCode="bold">Bacterial, viral and other infections due to opportunistic pathogens. </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Closely monitor patients for signs and symptoms of infection during treatment with KEVZARA. If a serious infection develops, interrupt KEVZARA until the infection is controlled.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Consider the risks and benefits of treatment with KEVZARA prior to initiating therapy in patients with chronic or recurrent infection.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISK OF SERIOUS INFECTIONS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning</content>.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Serious infections leading to hospitalization or death including bacterial, viral, invasive fungal, and other opportunistic infections have occurred in patients receiving KEVZARA. (<linkHtml href="#S5.1">5.1</linkHtml>) </content>
                           </item>
                           <item>
                              <content styleCode="bold">If a serious infection develops, interrupt KEVZARA until the infection is controlled. (<linkHtml href="#S5.1">5.1</linkHtml>) </content>
                           </item>
                           <item>
                              <content styleCode="bold">Cases of tuberculosis (TB) have been reported. Prior to starting KEVZARA, test for latent TB; if positive, start treatment for TB. (<linkHtml href="#S5.1">5.1</linkHtml>) </content>
                           </item>
                           <item>
                              <content styleCode="bold">Closely monitor patients for signs and symptoms of infection during treatment with KEVZARA. (<linkHtml href="#S5.1">5.1</linkHtml>) </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="6f33b141-8e1f-4956-8592-933068533241"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <colgroup>
                              <col width="80%" align="left" valign="top"/>
                              <col width="20%" align="right" valign="top"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="left">Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td align="right">6/2024</td>
                              </tr>
                              <tr>
                                 <td align="left">Dosage and Administration (<linkHtml href="#S2">2</linkHtml>)</td>
                                 <td align="right">6/2024</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="eb86d4bb-26df-4a7a-abdb-cae4b58a7c40"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>KEVZARA<sup>Â®</sup> is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:</paragraph>
                        <list styleCode="disc" listType="unordered">
                           <item>adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                           <item>patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="c7378fef-0df4-4832-9020-699c1fe8ec74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Rheumatoid Arthritis (RA)</title>
                     <text>
                        <paragraph>KEVZARA<sup>Â®</sup> is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="47399cd2-f6ab-40f5-854e-2ee882fd024a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Polymyalgia Rheumatica (PMR)</title>
                     <text>
                        <paragraph>KEVZARA is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="11938066-5636-4681-ad87-7fa3a2b48b61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.3 Polyarticular Juvenile Idiopathic Arthritis (pJIA)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">KEVZARA is indicated for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="f6016cc5-da3e-46aa-af43-7f126982f0e6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">General Considerations for Administration</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>KEVZARA initiation is not recommended in patients with ANC less than 2,000/mm<sup>3</sup>, platelets less than 150,000/mm<sup>3</sup> or liver transaminases above 1.5 times ULN. See Full Prescribing Information (FPI) for complete information. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Recommended Dosage in RA</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage is 200 mg subcutaneously, once every 2 weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>For RA, KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Recommended Dosage in PMR</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage is 200 mg subcutaneously, once every two weeks   in combination with a tapering course of corticosteroids. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>For PMR, KEVZARA can be used as monotherapy following discontinuation of corticosteroids. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Recommended Dosage in pJIA</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage is 200 mg given subcutaneously once every 2 weeks for pJIA patients who weigh 63 kg or greater using the 200 mg/1.14 mL pre-filled syringe. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>For pJIA, KEVZARA can be used as monotherapy or in combination with conventional DMARDs. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Dosage Modifications for Cytopenias, Abnormal Liver Enzymes, Infections</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>See FPI for complete information. (<linkHtml href="#S2.6">2.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3521ddcb-1531-4f7d-8b66-e70c4a166171"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Considerations Prior to Administration</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="cc0c9b69-24e1-4045-a9b0-3a93f576d7cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Not Recommended for Concomitant Use with Biological DMARDS</content>
                              </paragraph>
                              <paragraph>The concurrent use of KEVZARA with biological DMARDs such as tumor necrosis factor (TNF) antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators has not been studied. Avoid using KEVZARA with biological DMARDs because of the possibility of increased immunosuppression and increased risk of infection.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9b96e916-4bfb-4319-962e-6c6a1df5b102"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Evaluations Prior to Treatment</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Complete blood count (CBC): Treatment initiation with KEVZARA is not recommended in patients with an absolute neutrophil count (ANC) below 2000 per mm<sup>3</sup>, or platelet count below 150,000 per mm<sup>3</sup>. Monitor laboratory parameters <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                                 </item>
                                 <item>Liver function tests (LFT): Treatment initiation with KEVZARA is not recommended in patients with or who have alanine transaminase (ALT) or aspartate aminotransferase (AST) above 1.5 times the upper limit of normal (ULN). Monitor laboratory parameters <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                                 <item>Lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol and/or triglycerides): Assess lipid parameters at baseline. Monitor laboratory parameters <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                                 </item>
                                 <item>Active and latent tuberculosis infection evaluation: Prior to initiating KEVZARA, test patients for active and latent tuberculosis (TB). KEVZARA should not be administered to patients with active TB. If positive for latent infection, consider treating for TB prior to KEVZARA use <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                                 </item>
                                 <item>Evaluate for infections: Avoid KEVZARA use in patients with active infections <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="e7e5797e-98ae-4954-b63c-14d1ca90def0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage for Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>The recommended dosage of KEVZARA is 200 mg once every two weeks given as a subcutaneous injection <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.</paragraph>
                        <paragraph>Modify the dosage as recommended in Table 1 if the patient develops neutropenia, thrombocytopenia, or liver enzyme abnormalities <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2d53e0b6-f539-417c-90fb-0cb76a891d8b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage for Polymyalgia Rheumatica</title>
                     <text>
                        <paragraph>The recommended dosage of KEVZARA is 200 mg once every two weeks given as a subcutaneous injection, in combination with a tapering course of systemic corticosteroids <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>. KEVZARA can be used as monotherapy following discontinuation of corticosteroids.</paragraph>
                        <paragraph>Discontinue KEVZARA if the patient develops neutropenia (using ANC results obtained at the end of the dosing interval), thrombocytopenia, or liver enzyme abnormalities <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="b5b35c03-6431-4a81-937d-769e34761b51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.4 Recommended Dosage for Polyarticular Juvenile Idiopathic Arthritis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage of KEVZARA for patients who weigh 63 kg and greater is 200 mg once every two weeks given as a subcutaneous injection (maximum dose 200 mg). Dosage in this patient population can be achieved by administering the 200 mg/1.14 mL pre-filled syringe. The pre-filled pen is not intended for use in pediatric patients <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> KEVZARA is not approved in pediatric patients weighing less than 63 kg because of the lack of an appropriate dosage form.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with pJIA, KEVZARA can be used alone or in combination with conventional DMARDs.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="74b1280c-a129-4f42-885f-92434f734afc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.5 Preparation and Administration Instructions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.  KEVZARA solution should be clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored or contains particles, or if any part of the pre-filled syringe or pre-filled pen appears to be damaged.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Rotate injection sites with each injection. Do not inject into skin that is tender, damaged, or has bruises or scars.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="08f2e915-6fe0-4f60-8dec-004a3f0ed357"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Pre-filled Pen and Pre-filled Syringe</content>
                                 </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="xmChange">KEVZARA is intended for use under the guidance of a healthcare professional. A patient may self-inject KEVZARA or the patient's caregiver may administer KEVZARA. Provide proper training to patients and/or caregivers on the preparation and administration of KEVZARA prior to use according to the Instructions for Use (IFU).</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Allow the pre-filled syringe to sit at room temperature for 30 minutes prior to subcutaneous injection. Do not warm KEVZARA in any other way.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">If using a pre-filled pen, allow the pre-filled pen to sit at room temperature for 60 minutes prior to subcutaneous injection. Do not warm KEVZARA in any other way. </content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Instruct patients to inject the full amount in the syringe or pen (1.14 mL), which provides 200 mg or 150 mg of KEVZARA, according to the directions provided in the IFU.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">The ability of pediatric patients to self-inject with the pre-filled pen has not been tested.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="df40e12b-c15e-4850-ab68-207e3be696e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications for Cytopenias, Abnormal Liver Enzymes, or Infections</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="d61f6b2e-b094-4afb-82e5-e5cb8c29cbcc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications for Patients with Rheumatoid Arthritis</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="underline">Laboratory Abnormalities</content>: Modify dosage in case of neutropenia, thrombocytopenia, or liver enzyme elevations as shown in Table 1 <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. For treatment initiation criteria, refer to the dosage recommendations for RA <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2)</linkHtml>]</content>.</item>
                              </list>
                              <table ID="t1" width="85%">
                                 <caption>Table 1: Dosage Modifications due to Neutropenia, Thrombocytopenia, or Elevated Liver Enzymes in Patients with Rheumatoid Arthritis</caption>
                                 <colgroup>
                                    <col width="30%" align="left" valign="top"/>
                                    <col width="70%" align="left" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td styleCode="Lrule Rrule" colspan="2" align="left">
                                          <content styleCode="bold">Low Absolute Neutrophil Count (ANC) </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">
                                          <content styleCode="bold">Lab Value (cells/mm<sup>3</sup>)</content>
                                       </td>
                                       <td styleCode="Rrule" align="left">
                                          <content styleCode="bold">Recommendation </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">ANC greater than 1,000</td>
                                       <td styleCode="Rrule" align="left">Maintain current dosage of KEVZARA.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">ANC 500 to 1,000</td>
                                       <td styleCode="Rrule" align="left">Hold treatment with KEVZARA until ANC greater than 1,000.<br/>KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">ANC less than 500</td>
                                       <td styleCode="Rrule" align="left">Discontinue KEVZARA.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="2" align="left">
                                          <content styleCode="bold">Low Platelet Count </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">
                                          <content styleCode="bold">Lab Value (cells/mm<sup>3</sup>)</content>
                                       </td>
                                       <td styleCode="Rrule" align="left">
                                          <content styleCode="bold">Recommendation </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">50,000 to 100,000</td>
                                       <td styleCode="Rrule" align="left">Hold treatment with KEVZARA until platelets greater than 100,000.<br/>KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">Less than 50,000</td>
                                       <td styleCode="Rrule" align="left">If confirmed by repeat testing, discontinue KEVZARA.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="2" align="left">
                                          <content styleCode="bold">Liver Enzyme Abnormalities</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">
                                          <content styleCode="bold">Lab Value</content>
                                       </td>
                                       <td styleCode="Rrule" align="left">
                                          <content styleCode="bold">Recommendation </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">ALT or AST greater than ULN to 3 times ULN</td>
                                       <td styleCode="Rrule" align="left">Consider dosage modification of concomitant DMARDs as clinically appropriate.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">ALT or AST greater than 3 times ULN to 5 times ULN</td>
                                       <td styleCode="Rrule" align="left">Hold treatment with KEVZARA until ALT or AST less than 3 times ULN.<br/>KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" align="left">ALT or AST greater than 5 times ULN</td>
                                       <td styleCode="Rrule" align="left">Discontinue KEVZARA.</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="underline">Infections:</content> If a patient with RA develops a serious infection or an opportunistic infection, hold treatment with KEVZARA until the infection is controlled <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="16c29c48-b819-4ba7-9964-c92383437454"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Modifications for Patients with Polymyalgia Rheumatica</content>
                              </paragraph>
                              <list styleCode="disc" listType="unordered">
                                 <item>
                                    <content styleCode="underline">Laboratory Abnormalities</content>: Discontinue KEVZARA in patients with PMR who develop the following laboratory abnormalities <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>:<list styleCode="circle" listType="unordered">
                                       <item>neutropenia (ANC below 1,000 per mm<sup>3</sup> at the end of the dosing interval)</item>
                                       <item>thrombocytopenia (platelet count below 100,000 per mm<sup>3</sup>)</item>
                                       <item>AST or ALT elevations 3 times above the ULN</item>
                                    </list>
                                    <br/>Dosage modifications have not been studied in patients with PMR with these conditions. For treatment initiation criteria, refer to the dosage recommendations for PMR <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.</item>
                                 <item>
                                    <content styleCode="underline">Infections</content>: If a patient with PMR develops a serious infection or an opportunistic infection, hold treatment with KEVZARA until the infection is controlled <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="280f6a43-6b01-4cd2-98c0-a0eb45f97764"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Dosage Modification for Patients with Polyarticular Juvenile Idiopathic Arthritis</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Dose reduction of KEVZARA has not been studied in the pJIA population. Discontinue KEVZARA if ALT &gt;5 ULN, platelet count â¤50,000 cells/mm<sup>3</sup>, neutrophil count &lt;500 cells/mm<sup>3</sup> associated with infection. Hold KEVZARA dosing for ALT &gt;3 to â¤5 ULN, platelet count &gt;50,000 to â¤100,000 cells/mm<sup>3</sup>, and neutrophil count â¥500 to &lt;1000 cells/mm<sup>3</sup>, and until the clinical condition has been evaluated. The decision to discontinue KEVZARA should be based upon the medical assessment of the individual patient. If appropriate, the dose of concomitant methotrexate and/or other medications should be modified or discontinued.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="6b2717cd-ed75-4250-95c1-bc9e6746297f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 150 mg/1.14 mL and 200 mg/1.14 mL clear and colorless to pale-yellow solution in a single-dose pre-filled syringe.</paragraph>
                  <paragraph>Injection: 150 mg/1.14 mL and 200 mg/1.14 mL clear and colorless to pale-yellow solution in a single-dose pre-filled pen. </paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Injection: 150 mg/1.14 mL and 200 mg/1.14 mL solution in a single-dose pre-filled syringe (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>Injection: 150 mg/1.14 mL and 200 mg/1.14 mL solution in a single-dose pre-filled pen (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="72a10e0d-a674-4e65-8a50-32e89375883c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>KEVZARA is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>KEVZARA is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients. (<linkHtml href="#S4">4</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="12e76951-453e-4e06-9dd9-72c7992a3278"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Serious Infections: Avoid KEVZARA use during an active infection. (<linkHtml href="#S5.1">5.1</linkHtml>) </item>
                           <item>Neutropenia, Thrombocytopenia, Elevated Liver Enzymes, Lipid Abnormalities: Monitor laboratory parameters. (<linkHtml href="#S5.2">5.2</linkHtml>) </item>
                           <item>Gastrointestinal (GI) Perforation: Risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroids. Promptly evaluate acute abdominal signs or symptoms. (<linkHtml href="#S5.3">5.3</linkHtml>) </item>
                           <item>Hypersensitivity reactions. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Live vaccines: Avoid use with KEVZARA. (<linkHtml href="#S5.7">5.7</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="fd259d94-4b33-4572-b0a9-25efb5eb8b0d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Serious Infections</title>
                     <text>
                        <paragraph>Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving immunosuppressive agents including KEVZARA. Among opportunistic infections, tuberculosis, candidiasis, and pneumocystis were reported with KEVZARA. Some patients presented with disseminated rather than localized disease and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. The most frequently observed serious infections with KEVZARA in RA patients included pneumonia and cellulitis <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. While not reported in KEVZARA clinical studies, other serious infections (e.g., histoplasmosis, cryptococcus, aspergillosis) have been reported in patients receiving other immunosuppressive agents for the treatment of RA.</paragraph>
                        <paragraph>Avoid use of KEVZARA in patients with an active infection, including localized infections. Consider the risks and benefits of treatment prior to initiating KEVZARA in patients who have:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>chronic or   recurrent infection;</item>
                           <item>a history of   serious or opportunistic infections;</item>
                           <item>underlying   conditions that may predispose them to infection;</item>
                           <item>been exposed   to tuberculosis; or</item>
                           <item>lived in or traveled to areas of endemic tuberculosis or endemic mycoses.</item>
                        </list>
                        <paragraph>Closely monitor patients for the development of signs and symptoms of infection during treatment with KEVZARA, as signs and symptoms of acute inflammation may be lessened due to suppression of the acute phase reactants <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Hold treatment with KEVZARA if a patient develops a serious infection or an opportunistic infection.</paragraph>
                        <paragraph>Perform prompt and complete diagnostic testing appropriate for an immunocompromised patient who develops a new infection during treatment with KEVZARA; initiate appropriate antimicrobial therapy, and closely monitor the patient.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="1463ea17-24e3-4432-b2ff-d359e682b067"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tuberculosis</content>
                              </paragraph>
                              <paragraph>Evaluate patients for tuberculosis (TB) risk factors and test for latent infection prior to initiating treatment with KEVZARA. Treat patients with latent TB with standard antimycobacterial therapy before initiating KEVZARA. Consider anti-TB therapy prior to initiation of KEVZARA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but having risk factors for TB infection. When considering anti-TB therapy, consultation with a physician with expertise in TB may be appropriate.</paragraph>
                              <paragraph>Closely monitor patients for the development of signs and symptoms of TB including patients who tested negative for latent TB infection prior to initiating therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="39e543c6-42ea-4c8e-b21e-348f090e84fc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Viral Reactivation</content>
                              </paragraph>
                              <paragraph>Viral reactivation has been reported with immunosuppressive biologic therapies. Cases of herpes zoster were observed in clinical studies with KEVZARA <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. The risk of Hepatitis B reactivation with KEVZARA is unknown since patients who were at risk for reactivation were excluded.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="e0069fd7-a77c-46cf-b1dc-b641704cac87"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Laboratory Abnormalities</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="3ac6809c-d2de-4075-a4a6-92e550a39f44"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Neutropenia</content>
                              </paragraph>
                              <paragraph>Treatment with KEVZARA was associated with a higher incidence of decrease in absolute neutrophil count (ANC), including neutropenia <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Assess   neutrophil count prior to initiation of KEVZARA and monitor neutrophil   count 4 to 8 weeks after start of therapy and every 3 months thereafter <content styleCode="italics">[see   <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. For recommendations regarding initiating   KEVZARA therapy and dosage modifications based on ANC results see <content styleCode="italics">
                                       <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml> and <linkHtml href="#S2.6">2.6)</linkHtml>
                                    </content>.</item>
                                 <item>Based on the   pharmacodynamics of the changes in ANC <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>,   use results obtained at the end of the dosing interval when considering dosage modification.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="93735312-2bdf-4be2-9f9c-a7704201ad8e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Thrombocytopenia</content>
                              </paragraph>
                              <paragraph>Treatment with KEVZARA was associated with a reduction in platelet counts in clinical studies <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Assess   platelet count prior to initiation of KEVZARA and monitor platelets 4 to 8   weeks after start of therapy and every 3 months thereafter. For recommendations   regarding initiating KEVZARA therapy and dosage modifications based on   platelet counts see <content styleCode="italics">
                                       <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml> and <linkHtml href="#S2.6">2.6)</linkHtml>
                                    </content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="893b91e8-f78a-4fc3-8eb6-315df8f8f8aa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elevated Liver Enzymes</content>
                              </paragraph>
                              <paragraph>Treatment with KEVZARA was associated with a higher incidence of transaminase elevations. These elevations were transient and did not result in any clinically evident hepatic injury in clinical studies <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Increased frequency and magnitude of these elevations were observed when potentially hepatotoxic drugs (e.g., MTX) were used in combination with KEVZARA.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Assess   ALT/AST levels prior to initiation of KEVZARA and monitor ALT and AST   levels 4 to 8 weeks after start of therapy and every 3 months thereafter.   When clinically indicated, consider other liver function tests such as   bilirubin. For recommendations regarding initiating KEVZARA therapy and dosage   modifications based on transaminase elevations see <content styleCode="italics">
                                       <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml> and <linkHtml href="#S2.6">2.6)</linkHtml>
                                    </content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="baa3de7b-2273-4494-87d2-d072a81f64eb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Lipid Abnormalities</content>
                              </paragraph>
                              <paragraph>Treatment with KEVZARA was associated with increases in lipid parameters such as LDL cholesterol, HDL cholesterol and/or triglycerides <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Assess lipid   parameters approximately 4 to 8 weeks following initiation of treatment   with KEVZARA, then at approximately 6-month intervals.</item>
                                 <item>Manage   patients according to clinical guidelines for the management of   hyperlipidemia.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="1b756f21-e89e-4de8-bfd0-c51455dfb8f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Gastrointestinal Perforation</title>
                     <text>
                        <paragraph>Gastrointestinal perforations have been reported in clinical studies, primarily as complications of diverticulitis. GI perforation risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroids. Promptly evaluate patients presenting with new onset abdominal symptoms <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="74060564-eab4-40a6-a260-fdcf251632ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Immunosuppression</title>
                     <text>
                        <paragraph>Treatment with immunosuppressants may result in an increased risk of malignancies. The impact of treatment with KEVZARA on the development of malignancies is not known but malignancies were reported in clinical studies <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="cb1ff19c-2060-44ac-9f6e-a9602f861649"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions have been reported in association with KEVZARA <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> Hypersensitivity reactions that required treatment discontinuation were reported in 0.3% of patients in controlled RA trials. Injection site rash, rash, and urticaria were the most frequent hypersensitivity reactions. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of KEVZARA immediately. Do not administer KEVZARA to patients with known hypersensitivity to sarilumab <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="ed5b0542-1b26-4ecf-a7dd-e34fa4bcf507"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Active Hepatic Disease and Hepatic Impairment</title>
                     <text>
                        <paragraph>Treatment with KEVZARA is not recommended in patients with active hepatic disease or hepatic impairment, as treatment with KEVZARA was associated with transaminase elevations <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="5565fa2d-090b-406e-9bf0-149068d3b504"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Live Vaccines</title>
                     <text>
                        <paragraph>Avoid concurrent use of live vaccines during treatment with KEVZARA due to potentially increased risk of infections; clinical safety of live vaccines during KEVZARA treatment has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving KEVZARA. Prior to initiating treatment, it is recommended that all patients be brought up to date with all immunizations in agreement with current immunization guidelines. The interval between live vaccinations and initiation of KEVZARA therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="a8e550b1-bee9-414c-99f1-d9bcb3fc8f43"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered">
                     <item>Serious infections<content styleCode="italics"> [see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Neutropenia, thrombocytopenia, elevated liver enzymes, lipid abnormalities <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Gastrointestinal perforation <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Immunosuppression <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are:</paragraph>
                        <list styleCode="disc" listType="unordered">
                           <item>
                              <content styleCode="underline">Rheumatoid Arthritis (incidence â¥3 %):</content> neutropenia, increased ALT, injection site erythema, upper respiratory infections and urinary tract infections. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Polymyalgia Rheumatica (incidence â¥ 5%):</content> neutropenia, leukopenia and injection site pruritus. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Polyarticular Juvenile Idiopathic Arthritis:</content> nasopharyngitis, neutropenia, upper respiratory tract infection and injection site erythema. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 									</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="f3cff964-b33f-4f82-aaeb-aa4f6ba223d7"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="f646ea3b-a8b4-4bd0-85a2-630787065006"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Rheumatoid Arthritis</content>
                              </paragraph>
                              <paragraph>All patients in the safety data described below had moderately to severely active rheumatoid arthritis.</paragraph>
                              <paragraph>The safety of KEVZARA in combination with conventional DMARDs was evaluated based on data from seven studies, of which two were placebo-controlled, consisting of 2887 patients (long-term safety population). Of these, 2170 patients received KEVZARA for at least 24 weeks, 1546 for at least 48 weeks, 1020 for at least 96 weeks, and 624 for at least 144 weeks.</paragraph>
                              <paragraph>The pre-rescue placebo-controlled population includes patients from the two Phase 3 efficacy studies (Studies 1 and 2) from weeks 0 to 16 for Study 1 and weeks 0 to 12 for Study 2, and was used to assess common adverse reactions and laboratory abnormalities prior to patients being permitted to switch from placebo to KEVZARA. In this population, 582 patients, 579 patients, and 579 patients received KEVZARA 200 mg, KEVZARA 150 mg, or placebo once every two weeks, respectively, in combination with conventional DMARDs.</paragraph>
                              <paragraph>The 52-week placebo-controlled population includes patients from one Phase 2 study of 12-week duration and two Phase 3 efficacy studies (one of 24-week duration and the other of 52-week duration). This placebo-controlled population includes all subjects from the double-blind, placebo-controlled periods from each study and was analyzed under their original randomization assignment. In this population, 661 patients, 660 patients, and 661 patients received KEVZARA 200 mg, KEVZARA 150 mg, or placebo once every two weeks, respectively, in combination with conventional DMARDs.</paragraph>
                              <paragraph>Most safety data are described for the pre-rescue population. For rarer events, the 52-week placebo-controlled population is used.</paragraph>
                              <paragraph>The most common serious adverse reactions were infections<content styleCode="italics">.</content>
                              </paragraph>
                              <paragraph>The most frequent adverse reactions (occurring in at least 3% of patients treated with KEVZARA in combination with DMARDs) observed with KEVZARA in the clinical studies were neutropenia, increased ALT, injection site erythema, upper respiratory infections, and urinary tract infections.</paragraph>
                              <paragraph>In the pre-rescue placebo-controlled population, premature discontinuation due to adverse reactions occurred in 8%, 6% and 3% of patients treated with KEVZARA 200 mg, KEVZARA 150 mg, and placebo, respectively.</paragraph>
                              <paragraph>The most common adverse reaction (greater than 1%) that resulted in discontinuation of therapy with KEVZARA was neutropenia.</paragraph>
                              <paragraph>The use of KEVZARA as monotherapy was assessed in 132 patients, of which 67 received KEVZARA 200 mg and 65 patients received KEVZARA 150 mg without concomitant DMARDs. The safety profile was generally consistent with that in the population receiving concomitant DMARDs.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ff9590ce-9fc7-434c-a51e-49dde4d1b4d7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Overall Infections</paragraph>
                              <paragraph>In the pre-rescue placebo-controlled population, the rate of infections in the 200 mg and 150 mg KEVZARA + DMARD group was 110 and 105 events per 100 patient-years, respectively, compared to 81 events per 100 patient-years in the placebo + DMARD group. The most commonly reported infections (2% to 4% of patients) were upper respiratory tract infections, urinary tract infections, and nasopharyngitis.</paragraph>
                              <paragraph>In the 52-week placebo-controlled population, 0.8% of patients (5 patients) treated with KEVZARA 200 mg + DMARD, 0.6% (4 patients) treated with KEVZARA 150 mg + DMARD and 0.5% (3 patients) treated with placebo + DMARD had an event of herpes zoster <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                              <paragraph>The overall rate of infections with KEVZARA + DMARD in the long-term safety population was consistent with rates in the controlled periods of the studies.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="af9c3053-882b-4f13-85e6-2f49b69723ac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Serious Infections</content>
                              </paragraph>
                              <paragraph>In the pre-rescue population, the rate of serious infections in the 200 mg and 150 mg KEVZARA + DMARD group was 3.8  and 4.4 events per 100 patient-years, respectively, compared to 2.5 events per 100 patient-years in the placebo + DMARD group. In the 52-week placebo-controlled population, the rate of serious infections in the 200 mg and 150 mg KEVZARA + DMARD group was 4.3 and 3.0 events per 100 patient-years, respectively, compared to 3.1 events per 100 patient-years in the placebo + DMARD group.</paragraph>
                              <paragraph>In the long-term safety population, the overall rate of serious infections was consistent with rates in the controlled periods of the studies. The most frequently observed serious infections included pneumonia and cellulitis. Cases of opportunistic infection have been reported <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a5ed03e2-29a1-4857-ad03-2bc86082aa24"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Gastrointestinal Perforation</paragraph>
                              <paragraph>In the 52-week placebo-controlled population, one patient on KEVZARA therapy experienced a gastrointestinal (GI) perforation (0.11 events per 100 patient-years).</paragraph>
                              <paragraph>In the long-term safety population, the overall rate of GI perforation was consistent with rates in the controlled periods of the studies. Reports of GI perforation were primarily reported as complications of diverticulitis including lower GI perforation and abscess. Most patients who developed GI perforations were taking concomitant nonsteroidal anti-inflammatory medications (NSAIDs) or corticosteroids. The contribution of these concomitant medications relative to KEVZARA in the development of GI perforations is not known <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="802caead-9fa5-481b-ac18-3a8bd6d2c8dc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Hypersensitivity Reactions</paragraph>
                              <paragraph>In the pre-rescue placebo-controlled population, the proportion of patients who discontinued treatment due to hypersensitivity reactions was higher among those treated with KEVZARA (0.3% in 200 mg, 0.2% in 150 mg) than placebo (0%). The rate of discontinuations due to hypersensitivity in the long-term safety population was consistent with the placebo-controlled period.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="94e0f8c4-6b3b-4dd0-8237-ca204c235e83"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Injection Site Reactions</paragraph>
                              <paragraph>In the pre-rescue placebo-controlled population, injection site reactions were reported in 7% of patients receiving KEVZARA 200 mg, 6% receiving KEVZARA 150 mg, and 1% receiving placebo. These injection site reactions (including erythema and pruritus) were mild in severity for the majority of patients and necessitated drug discontinuation in 2 (0.2%) patients receiving KEVZARA.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e98fd85a-5620-4291-a860-50f5a49bc88d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Laboratory Abnormalities</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="1f06daa4-70c3-481c-9bed-2c2012ef4592"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased neutrophil count</content>
                                    </paragraph>
                                    <paragraph>In the pre-rescue placebo-controlled population, decreases in neutrophil counts less than 1000 per mm<sup>3</sup> occurred in 6% and 4% of patients in the 200 mg KEVZARA + DMARD and 150 mg KEVZARA + DMARD group, respectively, compared to no patients in the placebo + DMARD groups. Decreases in neutrophil counts less than 500 per mm<sup>3</sup> occurred in 0.7% of patients in both the 200 mg KEVZARA + DMARD and 150 mg KEVZARA + DMARD groups. Decrease in ANC was not associated with the occurrence of infections, including seriou<content styleCode="italics">s</content> infections.</paragraph>
                                    <paragraph>In the long-term safety population, the observations on neutrophil counts were consistent with what was seen in the placebo-controlled clinical studies <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="437eebed-e110-468e-85bb-d165d90b36ba"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased platelet count</content>
                                    </paragraph>
                                    <paragraph>In the pre-rescue placebo-controlled population, decreases in platelet counts less than 100,000 per mm<sup>3</sup> occurred in 1% and 0.7% of patients on 200 mg and 150 mg KEVZARA + DMARD, respectively, compared to no patients on placebo + DMARD, without associated bleeding events.</paragraph>
                                    <paragraph>In the long-term safety population, the observations on platelet counts were consistent with what was seen in the placebo-controlled clinical studies <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="fafdc358-023b-41ec-8da4-58e5c38f8e0f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elevated liver enzymes</content>
                                    </paragraph>
                                    <paragraph>Liver enzyme elevations in the pre-rescue placebo-controlled population (KEVZARA + DMARD or placebo + DMARD) are summarized in Table 2. In patients experiencing liver enzyme elevation, modification of treatment regimen, such as interruption of KEVZARA or reduction in dose, resulted in decrease or normalization of liver enzymes <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>. These elevations were not associated with clinically relevant increases in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic impairment <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                                    <table width="85%" ID="t2">
                                       <caption>Table 2: Incidence of Liver Enzyme Elevations in Adults with Moderately to Severely Active Rheumatoid Arthritis<footnote>Phase 3 placebo-controlled safety population through the pre-rescue period</footnote>
                                       </caption>
                                       <col width="25%" align="left" valign="top"/>
                                       <col width="25%" align="center" valign="top"/>
                                       <col width="25%" align="center" valign="top"/>
                                       <col width="25%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Placebo + DMARD<br/>N=579</th>
                                             <th styleCode="Rrule">KEVZARA 150 mg + DMARD<br/>N=579</th>
                                             <th styleCode="Rrule">KEVZARA 200 mg + DMARD<br/>N=582</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="4" align="left" valign="top">ULN = Upper Limit of Normal</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">AST </content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Greater than ULN to 3 times ULN or less</td>
                                             <td styleCode="Rrule">15%</td>
                                             <td styleCode="Rrule">27%</td>
                                             <td styleCode="Rrule">30%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Greater than 3 times ULN to 5 times ULN</td>
                                             <td styleCode="Rrule">0%</td>
                                             <td styleCode="Rrule">1%</td>
                                             <td styleCode="Rrule">1%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Greater than 5 times ULN</td>
                                             <td styleCode="Rrule">0%</td>
                                             <td styleCode="Rrule">0.7%</td>
                                             <td styleCode="Rrule">0.2%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">ALT </content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Greater than ULN to 3 times ULN or less</td>
                                             <td styleCode="Rrule">25%</td>
                                             <td styleCode="Rrule">38%</td>
                                             <td styleCode="Rrule">43%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Greater than 3 times ULN to 5 times ULN</td>
                                             <td styleCode="Rrule">1%</td>
                                             <td styleCode="Rrule">4%</td>
                                             <td styleCode="Rrule">3%</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Greater than 5 times ULN</td>
                                             <td styleCode="Rrule">0%</td>
                                             <td styleCode="Rrule">1%</td>
                                             <td styleCode="Rrule">0.7%</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="71450eba-e2e9-4c4a-b31b-7d25a4ac807e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lipid Abnormalities</content>
                                    </paragraph>
                                    <paragraph>Lipid parameters (LDL, HDL, and triglycerides) were first assessed at 4 weeks following initiation of KEVZARA + DMARDs in the placebo-controlled population. Increases were observed at this time point with no additional increases observed thereafter. Changes in lipid parameters from baseline to Week 4 are summarized below:</paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Mean LDL increased by 12 mg/dL in   the KEVZARA 150 mg every two weeks + DMARD group and 16 mg/dL in the   KEVZARA 200 mg every two weeks + DMARD group.</item>
                                       <item>Mean triglycerides increased by   20 mg/dL in the KEVZARA 150 mg every two weeks + DMARD group and 27 mg/dL in   the KEVZARA 200 mg every two weeks + DMARD group.</item>
                                       <item>Mean HDL   increased by 3 mg/dL in both the KEVZARA 150 mg every two weeks + DMARD   and KEVZARA 200 mg every two weeks + DMARD groups.</item>
                                    </list>
                                    <paragraph>In the long-term safety population, the observations in lipid parameters were consistent with what was observed in the placebo-controlled clinical studies.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5c37f03f-3446-441c-b1fa-0e8f03a95e4d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Malignancies</paragraph>
                              <paragraph>In the 52-week placebo-controlled population, 9 malignancies (exposure-adjusted event rate of 1.0 event per 100 patient-years) were diagnosed in patients receiving KEVZARA + DMARD compared to 4 malignancies in patients in the control group (exposure-adjusted event rate of 1.0 event per 100 patient-years).</paragraph>
                              <paragraph>In the long-term safety population, the rate of malignancies was consistent with the rate observed in the placebo-controlled period <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e1fad8d1-a258-4f41-a6d0-8bff8b8373c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Other Adverse Reactions</paragraph>
                              <paragraph>Adverse reactions occurring in 2% or more of patients on KEVZARA + DMARD and greater than those observed in patients on placebo + DMARD are summarized in Table 3.</paragraph>
                              <table width="85%" ID="t3">
                                 <caption>Table 3: Common Adverse Reactions<footnote>Adverse reactions occurring in 2% or more in the 150 mg KEVZARA + DMARD or 200 mg KEVZARA + DMARD groups and greater than observed in Placebo + DMARD</footnote> in Adults with Moderately to Severely Active Rheumatoid Arthritis <footnote>Pre-rescue, placebo-controlled population</footnote>
                                 </caption>
                                 <col width="35%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">Adverse Reactions</th>
                                       <th styleCode="Rrule">Placebo + DMARD<br/>(N=579)</th>
                                       <th styleCode="Rrule">KEVZARA 150 mg + DMARD<br/>(N=579)</th>
                                       <th styleCode="Rrule">KEVZARA 200 mg + DMARD<br/>(N=582)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neutropenia</td>
                                       <td styleCode="Rrule">0.2%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Alanine aminotransferase increased</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Injection site erythema</td>
                                       <td styleCode="Rrule">0.9%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Injection site pruritus</td>
                                       <td styleCode="Rrule">0.2%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertriglyceridemia</td>
                                       <td styleCode="Rrule">0.5%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">1%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Leukopenia</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">0.9%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Medically relevant adverse reactions occurring at an incidence less than 2% in patients with rheumatoid arthritis treated with KEVZARA in controlled studies was oral herpes.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c4260b47-fa4d-4710-859d-d184005fbda2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polymyalgia Rheumatica</content>
                              </paragraph>
                              <paragraph>Safety has been studied in one Phase 3 study (Study 3) in 117 PMR patients of whom 59 received subcutaneous KEVZARA 200 mg <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. Of these, 45 patients received KEVZARA for at least 24 weeks, 44 patients for at least 40 weeks, and 10 patients for at least 52 weeks. The total patient years duration in the KEVZARA PMR population was 47.37 patient years during the 12-month double blind, placebo-controlled study.</paragraph>
                              <paragraph>The common adverse reactions occurring in â¥5% of patients treated with KEVZARA were neutropenia (15.3%), leukopenia (6.8%), constipation (6.8%), rash pruritic (5.1%), myalgia (6.8%), fatigue (5.1%), and injection site pruritus (5.1%).</paragraph>
                              <paragraph>Serious adverse reactions of neutropenia occurred in 2 patients (3.4%) in the KEVZARA group compared to none in the placebo group. In both cases of neutropenia, the participants had a neutrophil count less than 500 per mm<sup>3</sup> without any infections and resolved following permanent discontinuation of study drug.</paragraph>
                              <paragraph>The most common adverse reactions that resulted in permanent discontinuation of therapy with KEVZARA were neutropenia in 3 patients (5.1%) and infection in 3 separate patients (5.1%), including COVID-19 (n=1), intervertebral discitis (n=1), and pneumonia (n=1).</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="99af6f62-9a4c-462d-89aa-d603eea6e1a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Overall Infections</paragraph>
                              <paragraph>In Study 3, the  proportion of patients with infections was lower in the KEVZARA group (37.3%) compared to the placebo group (50.0%). Two patients (3.2%) in the KEVZARA group and 1 patient (1.7%) in the placebo group had an event of herpes zoster.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="0c222b2b-837d-4c32-ac14-ef3d7bb3de6b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Serious infections</content>
                                    </paragraph>
                                    <paragraph>In Study 3, the proportion of patients with serious infections was similar in the KEVZARA group (5.1%) compared to the placebo group (5.2%).</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4ad54e12-35eb-493e-94f1-e1ed8affb95e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Injection Site Reactions</paragraph>
                              <paragraph>In Study 3, three patients (5.1%) in the KEVZARA group experienced injection site reactions of pruritus which were mild in severity. No patient in the placebo group experienced injection site reactions.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a633103f-a646-4326-b612-855cabafd195"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Laboratory Abnormalities</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="03f099df-2a65-4e8a-b8af-fad1b1e2a04a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased neutrophil count</content>
                                    </paragraph>
                                    <paragraph>In Study 3, decreases in neutrophil counts less than 1,000 per mm<sup>3</sup> occurred in 12% of the KEVZARA treated group and no patient in the placebo treated group. Decreases in neutrophil counts less than 500 per mm<sup>3</sup> occurred in 3.4% of patients in KEVZARA treated group compared to no patient in the placebo treated group.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5b922855-48ea-4f10-925c-301df8292449"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased platelet count</content>
                                    </paragraph>
                                    <paragraph>In Study 3, decreases in platelet counts between 75,000 to 100,000 per mm<sup>3</sup> occurred in two patients (3.4%) in the KEVZARA group, compared to no patient in the placebo treated group. These platelet count decreases were transient and not associated with bleeding events.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cd4a21c1-2781-4c7b-8c64-29f3194600e3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elevated liver enzymes</content>
                                    </paragraph>
                                    <paragraph>In Study 3, no KEVZARA treated patients had an ALT or AST greater than 3 times the upper limit of normal (ULN). In the placebo treated group, 2 patients had ALT elevations greater than 3 times the ULN.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="f2f71eeb-060d-42f1-900b-1ddc80942a72"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lipid Abnormalities</content>
                                    </paragraph>
                                    <paragraph>In Study 3, cholesterol levels â¥299.27 mg/dL were observed in 8/58 (13.8%) patients in the KEVZARA group compared to 4/58 (6.9%) patients in the placebo group. Triglycerides â¥407.4 mg/dL were observed in 3/58 (5.2%) patients in the KEVZARA group compared to 1/58 (1.7%) in the placebo group.</paragraph>
                                    <paragraph>No significant differences in mean HDL between KEVZARA group and placebo group were observed. At Week 52, mean increase from baseline for LDL and triglycerides levels were observed in the KEVZARA group though both remained within the normal range.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b4a895fc-c4e1-494d-ab89-98c0c1119c82"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polyarticular Juvenile Idiopathic Arthritis (pJIA)</content>
                              </paragraph>
                              <paragraph>The safety of KEVZARA was studied in patients 2 to 17 years of age with pJIA who have had an inadequate response to current therapy (Study 4) <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>. A total of 93 patients received at least one administration of the recommended dose: 79 (84.9%) patients received the recommended dose for 52 weeks, 53 (57%) patients received it for 96 weeks and 30 (32.2%) patients received it for 156 weeks.</paragraph>
                              <paragraph>The overall median duration of study treatment for the recommended dose was 672 days. The cumulative exposure to treatment for patients who received the recommended dose at any time during the study was 184.1 patient-years.</paragraph>
                              <paragraph>The most common adverse drug reactions were nasopharyngitis, neutropenia, upper respiratory tract infection, and injection site erythema.</paragraph>
                              <paragraph>The most common adverse drug reaction that resulted in permanent discontinuation of therapy with KEVZARA was neutropenia (5.4%).</paragraph>
                              <paragraph>No new adverse reactions and safety concerns were identified in the pJIA population compared to the RA population.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="62a450f1-6445-4016-a3f7-dc51b1dd1500"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Infections</paragraph>
                              <paragraph>In Study 4, the rate of infections was 146.6 events per 100 patient-years. The most common infections observed were nasopharyngitis (36.6%) and upper respiratory tract infections (URTI) (14.0%).</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="86764de7-1c9a-44ee-a5c8-7fdf2cbc3e81"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Injection Site Reactions</paragraph>
                              <paragraph>In Study 4, injection site reactions (ISRs) occurred in 13 (14.0%) patients and the most commonly reported ISR was injection site erythema (9.7%). The majority of these events were mild and none of the ISRs required patient withdrawal from treatment or dose interruption.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="157bce13-d834-4e8e-b7f1-74566d73b537"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Laboratory Abnormalities</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="0b54b8dc-b0ae-47a6-b542-267b0cc29edd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decrease neutrophil count</content>
                                    </paragraph>
                                    <paragraph>In Study 4, decreases in neutrophil counts less than 1000 per mm<sup>3</sup> occurred in 10/52 (19.2%) patients weighing in â¥30 kg and 20/41 (48.8%) patients weighing 10 to &lt;30 kg. The frequency of decreased neutrophil count was higher until Week 12. Decrease in ANC was not associated with an occurrence of infections, including serious infections.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d0991662-5932-4427-8f5b-b15bf2df6090"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decrease monocyte count</content>
                                    </paragraph>
                                    <paragraph>In Study 4, decrease in monocyte counts occurred in 4 (4.3%) patients and were mild in severity and non-serious.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5661e65a-b782-4815-a6c0-8bfacd27fd96"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elevated liver enzymes</content>
                                    </paragraph>
                                    <paragraph>In Study 4, nine (9.7%) patients had ALT increases, including one (1.1%) patient who had ALT &gt;3 times upper limit of normal (ULN) and up to â¤5 times ULN, and two (2.2%) patients who had ALT increases &gt;5 times ULN and up to â¤10 times ULN that resulted in permanent discontinuation. All patients recovered.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="f041a930-144a-4246-87c0-d616a539a43e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lipid Abnormalities</content>
                                    </paragraph>
                                    <paragraph>In Study 4, triglyceride levels of â¥150 mg/dL (1 Ã ULN) were observed in one (1.1%) patient. Three (3.2%) patients overall had elevation in triglycerides, and all were mild in severity and non-serious. No significant changes in mean LDL, HDL or total cholesterol were observed during the entire 156-week treatment period.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="00736472-97ae-4da6-b79d-bc9d20781a69"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250516"/>
               <component>
                  <section ID="S7.1">
                     <id root="32f70093-a4b1-4abd-9547-76f6ea6f4544"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Use with Other Drugs</title>
                     <text>
                        <paragraph>Population pharmacokinetic analyses did not detect any effect of methotrexate (MTX) on sarilumab clearance. KEVZARA has not been investigated in combination with JAK inhibitors or biological DMARDs such as TNF antagonists <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="484fea96-1ff5-4f92-8333-4c5df0110799"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Interactions with CYP450 Substrates </title>
                     <text>
                        <paragraph>Various <content styleCode="italics">in vitro</content> and limited <content styleCode="italics">in vivo</content> human studies have shown that cytokines and cytokine modulators can influence the expression and activity of specific cytochrome P450 (CYP) enzymes and therefore have the potential to alter the pharmacokinetics of concomitantly administered drugs that are substrates of these enzymes. Elevated interleukin-6 (IL-6) concentration may down-regulate CYP activity such as in patients with RA and hence increase drug levels compared to subjects without RA. Blockade of IL-6 signaling by IL-6RÎ± antagonists such as KEVZARA might reverse the inhibitory effect of IL-6 and restore CYP activity, leading to altered drug concentrations.</paragraph>
                        <paragraph>The modulation of IL-6 effect on CYP enzymes by KEVZARA may be clinically relevant for CYP substrates with a narrow therapeutic index, where the dose is individually adjusted. Upon initiation or discontinuation of KEVZARA, in patients being treated with CYP substrate medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., theophylline) and adjust the individual dose of the medicinal product as needed.</paragraph>
                        <paragraph>Exercise caution when co-administering KEVZARA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. The effect of KEVZARA on CYP450 enzyme activity may persist for several weeks after stopping therapy <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="d7edfa92-d6f6-4dab-8580-c8c88ab8d95e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Live Vaccines</title>
                     <text>
                        <paragraph>Avoid concurrent use of live vaccines during treatment with KEVZARA <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="649ebf20-7fdd-423d-a93b-60b87dba780d"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250516"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Lactation: Discontinue drug or nursing taking into consideration importance of drug to mother. (<linkHtml href="#S8.2">8.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="1e015558-7db8-433d-9b17-a0857b3bf3e0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="2905e93b-c441-4c66-9bb8-136cc35218f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>The limited human data with KEVZARA in pregnant women are not sufficient to inform drug-associated risk for major birth defects and miscarriage. Monoclonal antibodies, such as sarilumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant <content styleCode="italics">(see <linkHtml href="#cc">Clinical Considerations</linkHtml>)</content>. From animal data, and consistent with the mechanism of action, levels of IgG, in response to antigen challenge, may be reduced in the fetus/infant of treated mothers <content styleCode="italics">(see <linkHtml href="#cc">Clinical Considerations</linkHtml> and <linkHtml href="#Data">Data</linkHtml>)</content>. In an animal reproduction study, consisting of a combined embryo-fetal and pre- and postnatal development study with monkeys that received intravenous administration of sarilumab, there was no evidence of embryotoxicity or fetal malformations with exposures up to approximately 84 times the maximum recommended human dose (MRHD) <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>. The literature suggests that inhibition of IL-6 signaling may interfere with cervical ripening and dilatation and myometrial contractile activity leading to potential delays of parturition <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. KEVZARA should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section ID="cc">
                           <id root="bd22fe74-ca03-456a-be0b-81ce465f0820"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="42eaa022-de72-42f5-8302-b88a35ba036b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Fetal/Neonatal Adverse Reactions</paragraph>
                                    <paragraph>Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to KEVZARA in utero <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]. </content>From the animal data, and consistent with the mechanism of action, levels of IgG, in response to antigen challenge, may be reduced in the fetus/infant of treated mothers <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="ce4150c0-d971-40c5-ac33-215c79a8db7b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="fc1168a8-809d-46fd-8f65-f7c4e4b5e476"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Animal Data</paragraph>
                                    <paragraph>In a combined embryo-fetal and pre- and postnatal development study, pregnant cynomolgus monkeys received sarilumab at intravenous doses of 0, 5, 15, or 50 mg/kg/week from confirmation of pregnancy at gestation day (GD) 20, throughout the period of organogenesis (up to approximately GD 50), and continuing to natural birth of infants at around GD 165. Maintenance of pregnancy was not affected at any doses. Sarilumab was not embryotoxic or teratogenic with exposures up to approximately 84 times the MRHD (based on AUC with maternal intravenous doses up to 50 mg/kg/week). Sarilumab had no effect on neonatal growth and development evaluated up to one month after birth. Sarilumab was detected in the serum of neonates up to one month after birth, suggesting that the antibody had crossed the placenta.</paragraph>
                                    <paragraph>Following antigen challenge, decreased IgG titers attributed to the immunosuppressive action of sarilumab were evident in studies with older monkeys, with exposures up to approximately 80 times the MRHD (based on AUC with intravenous doses up to 50 mg/kg/week) and juvenile mice treated with an analogous antibody, which binds to murine IL-6RÎ± to inhibit IL-6 mediated signaling, at subcutaneous doses up to 200 mg/kg/week. These findings suggest the potential for decreased IgG titers, following antigen challenge, in infants of mothers treated with KEVZARA.</paragraph>
                                    <paragraph>Parturition is associated with significant increases of IL-6 in the cervix and myometrium. The literature suggests that inhibition of IL-6 signaling may interfere with cervical ripening and dilatation and myometrial contractile activity leading to potential delays of parturition. For mice deficient in IL-6 (ll6<sup>-/-</sup> null mice), parturition was delayed relative to wild-type (ll6<sup>+/+</sup>) mice. Administration of recombinant IL-6 to ll6-/- null mice restored the normal timing of delivery.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="fbaf4d45-ae90-4512-9daf-20c8042489e7"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="2effe3fb-051d-4df2-901c-1dbf1b635efb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>No information is available on the presence of sarilumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is present in human milk. If sarilumab is transferred into human milk, the effects of local exposure in the gastrointestinal tract and potential limited systemic exposure in the infant to sarilumab are unknown. The lack of clinical data during lactation precludes clear determination of the risk of KEVZARA to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KEVZARA and the potential adverse effects on the breastfed child from KEVZARA or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="f4671454-f4ac-4f14-8be0-e4a90b64f577"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>KEVZARA is approved for active polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients who weigh 63 kg or greater. Use of KEVZARA in this patient population is supported by evidence from adequate and well-controlled studies of KEVZARA in adults with RA, pharmacokinetic data from adult patients with RA, and a pharmacokinetic, pharmacodynamic, dose-finding, and safety study in pediatric patients with pJIA 2 years of age and older. KEVZARA is not approved in pediatric patients weighing less than 63 kg because of the lack of an appropriate dosage form <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S12.3">Pharmacokinetics (12.3)</linkHtml>, and <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>, <linkHtml href="#S14.3">14.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of KEVZARA have not been established in pediatric patients with pJIA below the age of 2 years.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="ad907837-970d-4980-9a0a-89fc5c0b38e8"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of patients with RA exposed to KEVZARA in clinical studies <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>)]</content>, 450 patients (15%) were 65 years of age and over, while 48 patients (1.6%) were 75 years and over. In clinical studies, no overall differences in safety and efficacy were observed between older and younger patients. The frequency of serious infections among KEVZARA and placebo-treated patients 65 years of age and older was higher than those under the age of 65. </paragraph>
                        <paragraph>Of the total number of patients with PMR exposed to KEVZARA in the clinical study (Study 3) <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, 16 patients (27.1%) were under 65 years of age, 33 patients (55.9%) were 65 to 75 years of age, and 10 patients (17.0%) were 75 years and over. The median age in the PMR study was 69.0 years and all patients were on baseline corticosteroid. There were no differences in the incidence of serious infections between the KEVZARA group and placebo group. In Study 3, no overall differences in safety were observed between older and younger patients.</paragraph>
                        <paragraph>As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="a6a887e0-8f40-429a-8b4a-6c38c3da86aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>The safety and efficacy of KEVZARA have not been studied in patients with hepatic impairment, including patients with positive HBV or HCV serology <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="2d03c93e-3296-427f-a2c6-0ffd2b2fc42f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment </title>
                     <text>
                        <paragraph>No dose adjustment is required in patients with mild to moderate renal impairment. KEVZARA has not been studied in patients with severe renal impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="b4291b43-00de-48ce-b5d7-9ea04721f479"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Sarilumab is a human recombinant monoclonal antibody of the IgG1 subclass that binds to the IL-6 receptor and has an approximate molecular weight of 150 kDa. Sarilumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.</paragraph>
                  <paragraph>KEVZARA (sarilumab) injection for subcutaneous administration is supplied as a sterile, clear and colorless to pale yellow, preservative-free solution of approximately pH 6.0. KEVZARA is supplied in a single-dose pre-filled syringe and pre-filled pen.</paragraph>
                  <paragraph>Each syringe  or pen delivers 1.14 mL of solution containing 150 mg or 200 mg of sarilumab, arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection, USP.</paragraph>
               </text>
               <effectiveTime value="20250516"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="638c5e69-592b-4696-9519-edbf5566c36e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250516"/>
               <component>
                  <section ID="S12.1">
                     <id root="588ffbbf-7dab-4c78-afd8-7015b1321814"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis. </paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="f4cd8967-d19b-42bd-a440-7cf4fdb6404a"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Following single-dose subcutaneous administration of sarilumab 200-mg and 150-mg in patients with RA, rapid reduction of CRP levels was observed. Levels were reduced to normal within 2 weeks after treatment initiation. Following single-dose sarilumab administration, in patients with RA, absolute neutrophil counts decreased to the nadir between 3 to 4 days and thereafter recovered towards baseline <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. Treatment with sarilumab resulted in decreases in fibrinogen and serum amyloid A, and increases in hemoglobin and serum albumin. In patients with pJIA, decreases in CRP, erythrocyte sedimentation rate (ESR) and neutrophil count were observed after KEVZARA administration.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="563f9e9f-392c-44d6-bbb6-0594dc09e299"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="a74e9ff8-d546-45c0-b3c8-bd1b9c1c9038"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Rheumatoid Arthritis</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="cecc9a15-1387-4552-8ef9-9a5facdafd07"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Absorption</paragraph>
                                    <paragraph>The pharmacokinetics of sarilumab were characterized in 1770 adult patients with rheumatoid arthritis (RA) treated with sarilumab which included 631 patients treated with 150 mg and 682 patients treated with 200 mg doses by subcutaneous injection every two weeks for up to 52 weeks. The median t<sub>max</sub> was observed in 2 to 4 days.</paragraph>
                                    <paragraph>At steady state, exposure over the dosing interval measured by area under curve (AUC) increased 2-fold with an increase in dose from 150 to 200 mg every two weeks. Steady state was reached in 14 to 16 weeks with a 2- to 3-fold accumulation compared to single dose exposure.</paragraph>
                                    <paragraph>For the 150 mg every two weeks dose regimen, the estimated mean (Â± SD) steady-state AUC, C<sub>min</sub> and C<sub>max </sub>of sarilumab were 202 Â± 120 mg.day/L, 6.35 Â± 7.54 mg/L, and 20.0 Â± 9.20 mg/L, respectively.</paragraph>
                                    <paragraph>For the 200 mg every two weeks dose regimen, the estimated mean (Â± SD) steady-state AUC, C<sub>min</sub> and C<sub>max </sub>of sarilumab were 395 Â± 207 mg.day/L, 16.5 Â± 14.1 mg/L, and 35.6 Â± 15.2 mg/L, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cc5d2946-d027-4ad0-8662-6e0b865fbaaf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Distribution</paragraph>
                                    <paragraph>In patients with RA, the apparent volume of distribution at steady state was 7.3 L.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="db9f2ebd-a624-4b77-b580-c0f4c1db3119"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Elimination</paragraph>
                                    <paragraph>Sarilumab is eliminated by parallel linear and non-linear pathways. At higher concentrations, the elimination is predominantly through the linear, non-saturable proteolytic pathway, while at lower concentrations, non-linear saturable target-mediated elimination predominates. The half-life of sarilumab is concentration-dependent. At 200 mg every 2 weeks, the concentration-dependent half-life is up to 10 days in patients with RA at steady state. At 150 mg every 2 weeks, the concentration-dependent half-life is up to 8 days in patients with RA at steady state.</paragraph>
                                    <paragraph>After the last steady state dose of 150 mg and 200 mg sarilumab, the median times to non-detectable concentration are 28 and 43 days, respectively.</paragraph>
                                    <paragraph>Population pharmacokinetic analyses in patients with RA revealed that there was a trend toward higher apparent clearance of sarilumab in the presence of anti-sarilumab antibodies.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                                 <component>
                                    <section>
                                       <id root="7f980f21-7428-4ecc-9709-08532793187a"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Metabolism</content>
                                          </paragraph>
                                          <paragraph>The metabolic pathway of sarilumab has not been characterized. As a monoclonal antibody sarilumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG. </paragraph>
                                       </text>
                                       <effectiveTime value="20250516"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="53e6a248-35f3-4096-86c5-9e7e6255259b"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Excretion</content>
                                          </paragraph>
                                          <paragraph>Monoclonal antibodies, including sarilumab, are not eliminated via renal or hepatic pathways.</paragraph>
                                       </text>
                                       <effectiveTime value="20250516"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b3e78372-745e-43a1-a7d0-34fbd9fd64c2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polymyalgia Rheumatica</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic profile of subcutaneous sarilumab in PMR patients was determined using a population pharmacokinetic analysis on a data set including 58 PMR patients treated with repeated subcutaneous administration of sarilumab 200 mg every two weeks. In general, pharmacokinetic exposures were higher in patients with PMR when compared to patients with RA. For this dose regimen, the estimated mean (Â± SD) steady-state AUC, C<sub>min</sub> and C<sub>max</sub> of sarilumab were 551 Â± 321 mg.day/L, 27.0 Â± 21.5 mg/L, and 46.5 Â± 23.0 mg/L, respectively. The median time to steady state in PMR patients was estimated to be 28 weeks. There was accumulation following subcutaneous administration of sarilumab 200 mg, with an accumulation ratio of approximately 6-fold based on the mean trough concentrations.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a9d809f7-5821-4205-9e7c-235e5ad99042"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polyarticular juvenile idiopathic arthritis (pJIA)</content>
                              </paragraph>
                              <paragraph>The pharmacokinetics of sarilumab in pJIA patients was characterized by a population pharmacokinetic analysis which included 101 pediatric patients 2 to 17 years of age who were treated with repeated subcutaneous doses of sarilumab.</paragraph>
                              <paragraph>For 3 mg/kg sarilumab (patients with a body weight â¥30 kg) given every 2 weeks, the estimated mean (Â±SD) steady-state AUC, Cmin, and Cmax of sarilumab were 276 Â± 121 mg.day/L, 9.57 Â± 5.84 mg/L, and 27.1 Â± 11.6 mg/L, respectively.</paragraph>
                              <paragraph>For 4 mg/kg sarilumab (patients with a body weight 10 to &lt;30 kg) given every 2 weeks, the estimated mean (Â± SD) steady-state AUC, Cmin, and Cmax of sarilumab were 395 Â± 101 mg.day/L, 14.4 Â± 9.81 mg/L, and 40.4 Â± 7.77 mg/L, respectively.</paragraph>
                              <paragraph>Steady state was reached in 12 to 28 weeks with a 2- to 4-fold accumulation compared to single dose exposure for 3 and 4 mg/kg q2w. Steady state concentrations were within the range of exposures in adult RA patients following 150 mg/200 mg every 2 weeks.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d2243a8e-b645-4e1a-a831-cfea0f05b924"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Population pharmacokinetic analyses in adult patients showed that age, gender and race did not meaningfully influence the pharmacokinetics of sarilumab. Although body weight influenced the pharmacokinetics of sarilumab, no dose adjustments are recommended for any of these demographics in adult patients.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="75ac0b88-1e3a-493d-8681-95414bdfc580"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Hepatic Impairment</paragraph>
                                    <paragraph>No formal study of the effect of hepatic impairment on the pharmacokinetics of sarilumab was conducted.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5191fc63-1f9d-4ffc-aab6-02535b76a041"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Renal Impairment</paragraph>
                                    <paragraph>No formal study of the effect of renal impairment on the pharmacokinetics of sarilumab was conducted. Based on population pharmacokinetic analysis of data from 1770 patients with RA, including patients with mild (creatinine clearance (CL<sub>cr</sub>): 60 to 90 mL/min; N=471 at baseline) or moderate (CL<sub>cr</sub>: 30 to 60 mL/min; N=74 at baseline) renal impairment, CL<sub>cr</sub> was correlated with sarilumab exposure. However, the effect of CL<sub>cr</sub> on exposure is not sufficient to warrant a dose adjustment <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>. Patients with severe renal impairment were not studied.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="73b01785-cceb-4b96-a836-8f6a1f1e5efd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug-Drug Interactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <section>
                                 <id root="96d4250d-57f0-4ac3-9dae-508507130e18"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>CYP450 Substrates</paragraph>
                                    <paragraph>Simvastatin is a CYP3A4 and OATP1B1 substrate. In 17 patients with RA, one week following a single 200-mg subcutaneous administration of sarilumab, exposure of simvastatin and simvastatin acid decreased by 45% and 36%, respectively<content styleCode="italics"> [see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250516"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="a67f5f93-8899-46ce-9c96-eba6fb82e49d"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to sarilumab in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</paragraph>
                        <paragraph>In the RA pre-rescue population, 4.0% of patients treated with KEVZARA 200 mg + DMARD, 5.7% of patients treated with KEVZARA 150 mg + DMARD and 1.9% of patients treated with placebo + DMARD, exhibited an anti-drug antibody (ADA) response. Neutralizing antibodies (NAb) were detected in 1.0% of patients on KEVZARA 200 mg + DMARD, 1.6% of patients on KEVZARA 150 mg + DMARD, and 0.2% of patients on placebo + DMARD.</paragraph>
                        <paragraph>In RA patients treated with KEVZARA monotherapy, 9.2% of patients exhibited an ADA response with 6.9% of patients also exhibiting NAbs. Prior to administration of KEVZARA, 2.3% of patients exhibited an ADA response.</paragraph>
                        <paragraph>No correlation was observed between ADA development and either loss of efficacy or adverse reactions in RA patients.</paragraph>
                        <paragraph>In the PMR population, 1 patient (1.8%) in the KEVZARA 200 mg + 14-week corticosteroid taper group exhibited an ADA response. None of the patients in the placebo + 52-week corticosteroid taper group exhibited an ADA response. Neutralizing antibodies were detected in the PMR patient with ADA response on KEVZARA 200 mg; the patient did not demonstrate a clinical response. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the safety, and/or effectiveness of sarilumab is unknown.</paragraph>
                        <paragraph>In the pJIA population, 3 (4.3%) patients treated with the recommended dose exhibited an anti-drug antibody (ADA) response. Neutralizing antibodies were detected in one pJIA patient with ADA response. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the safety, and/or effectiveness of sarilumab is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="ff1192c5-e9b0-4fe4-8380-48346df6a51f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250516"/>
               <component>
                  <section ID="S13.1">
                     <id root="041bb5c0-509b-4e49-833f-99827a0bc73b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term animal studies have been performed to establish the carcinogenicity potential of sarilumab. Literature indicates that the IL-6 pathway can mediate anti-tumor responses by promoting increased immune cell surveillance of the tumor microenvironment. However, available published evidence also supports that IL-6 signaling through the IL-6 receptor may be involved in pathways that lead to tumorigenesis. The malignancy risk in humans from an antibody that disrupts signaling through the IL-6 receptor, such as sarilumab, is presently unknown.</paragraph>
                        <paragraph>Fertility and reproductive performance were unaffected in male and female mice treated with an analogous antibody, which binds to murine IL-6RÎ± to inhibit IL-6 mediated signaling, at subcutaneous doses of 10, 25, and 100 mg/kg twice per week.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="e2eea98e-d1a9-4685-a50d-1757c7bfdc6b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250516"/>
               <component>
                  <section ID="S14.1">
                     <id root="67df5f6b-f742-4d0a-920b-f2ac10bf47de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Rheumatoid Arthritis</title>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="b42ba6e2-4272-41fd-8051-e86dccff9751"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Design of Clinical Studies in Adults with Moderately to Severely Active RA</content>
                              </paragraph>
                              <paragraph>The efficacy and safety of KEVZARA in RA were assessed in two randomized, double-blind, placebo-controlled multicenter studies (Study 1 and Study 2) in patients older than 18 years with moderately to severely active rheumatoid arthritis (RA) diagnosed according to American College of Rheumatology (ACR) criteria. Patients had at least 8 tender and 6 swollen joints at baseline.</paragraph>
                              <paragraph>Study 1 (NCT01061736) evaluated 1197 patients with moderately to severely active rheumatoid arthritis who had inadequate clinical response to methotrexate (MTX). Patients received subcutaneous KEVZARA 200 mg, KEVZARA 150 mg, or placebo every two weeks with concomitant MTX. After Week 16 in Study 1, patients with an inadequate response could have been rescued with KEVZARA 200 mg every two weeks.</paragraph>
                              <paragraph>Study 2 (NCT01146652) evaluated 546 patients with moderately to severely active rheumatoid arthritis who had an inadequate clinical response or were intolerant to one or more TNF-Î± antagonists. Patients received subcutaneous KEVZARA 200 mg, KEVZARA 150 mg, or placebo every two weeks with concomitant conventional DMARDs (MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine). After Week 12 in Study 2, patients with an inadequate response could have been rescued with KEVZARA 200 mg every two weeks.</paragraph>
                              <paragraph>In Studies 1 and 2, the primary endpoint was the proportion of patients who achieved an ACR20 response at Week 24. Other key endpoints evaluated included change from baseline in HAQ-DI at Week 16 in Study 1 and at Week 12 in Study 2, and change from baseline in van der Heijde-modified Total Sharp Score (mTSS) at Week 52 in Study 1.</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ad0ec35c-18a5-4943-9534-593355e2adc0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Response</content>
                              </paragraph>
                              <paragraph>The percentages of KEVZARA every two weeks + MTX/DMARD-treated patients achieving ACR20, ACR50 and ACR70 responses in Studies 1 and 2 are shown Table 4. In both studies, patients treated with either 200 mg or 150 mg of KEVZARA every two weeks + MTX/DMARD had higher ACR20, ACR50, and ACR70 response rates versus placebo + MTX/DMARD-treated patients at Week 24.</paragraph>
                              <paragraph>In Studies 1 and 2, a greater proportion of patients treated with KEVZARA 200 mg or 150 mg every two weeks plus MTX/DMARD achieved a low level of disease activity as measured by a Disease Activity Score 28-C-Reactive Protein (DAS28-CRP) &lt;2.6 compared with placebo + MTX/DMARD at the end of the studies (Table 4). In Study 1, the proportion of patients achieving DAS28-CRP &lt;2.6 who had at least 3 or more active joints at the end of Week 24 was 33.1%, 37.8% and 20%, in the KEVZARA 200 mg + MTX/DMARD arm, KEVZARA 150 mg + MTX/DMARD arm, and placebo arm respectively.</paragraph>
                              <table width="90%" ID="t4">
                                 <caption>Table 4: Clinical Response in Placebo-Controlled Studies 1 and 2 in Adults with Moderately to Severely Active RA<footnote>Patients who were rescued or discontinued were considered non-responders for the analyses included in this table. In Study 1, at week 52, 196, 270, and 270 patients remained on placebo, KEVZARA 150 mg, and KEVZARA 200 mg respectively.</footnote>
                                 </caption>
                                 <col width="22%" align="left" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="11%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" colspan="7" align="center">Percentage of Patients</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2"/>
                                       <th styleCode="Rrule" colspan="3">Study 1</th>
                                       <th styleCode="Rrule" colspan="3">Study 2</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Rrule" align="center">Placebo + MTX<br/>N=398</th>
                                       <th styleCode="Rrule">KEVZARA 150 mg + MTX<br/>N=400</th>
                                       <th styleCode="Rrule">KEVZARA 200 mg + MTX<br/>N=399<br/>
                                       </th>
                                       <th styleCode="Rrule">Placebo + DMARD(s)<footnote ID="t4f2">DMARDs in Study 2 included MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine.</footnote>
                                          <br/>N=181</th>
                                       <th styleCode="Rrule">KEVZARA 150 mg + DMARD(s)<footnoteRef IDREF="t4f2"/>
                                          <br/>N=181</th>
                                       <th styleCode="Rrule">KEVZARA 200 mg + DMARD(s)<footnoteRef IDREF="t4f2"/>
                                          <br/>N=184</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">ACR20</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 12</content>
                                       </td>
                                       <td styleCode="Rrule">34.7%</td>
                                       <td styleCode="Rrule">54.0%</td>
                                       <td styleCode="Rrule">64.9%</td>
                                       <td styleCode="Rrule">37.6%</td>
                                       <td styleCode="Rrule">54.1%</td>
                                       <td styleCode="Rrule">62.5%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnote ID="t4f3">Weighted estimate of the rate difference; CI=confidence interval</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">19.4%<br/>(12.6%, 26.1%)<br/>
                                       </td>
                                       <td styleCode="Rrule">30.2%<br/>(23.6%, 36.8%)<br/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">16.6%<br/>(6.7%, 26.5%)<br/>
                                       </td>
                                       <td styleCode="Rrule">25.3%<br/>(15.7%, 34.8%)<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 24</content>
                                          <footnote>Primary end point</footnote>
                                       </td>
                                       <td styleCode="Rrule">33.4%</td>
                                       <td styleCode="Rrule">58.0%</td>
                                       <td styleCode="Rrule">66.4%</td>
                                       <td styleCode="Rrule">33.7%</td>
                                       <td styleCode="Rrule">55.8%</td>
                                       <td styleCode="Rrule">60.9%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">24.6%<br/>(18.0%, 31.3%)</td>
                                       <td styleCode="Rrule">33.0%<br/>(26.5%, 39.5%)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">22.1%<br/>(12.6%, 31.6%)<br/>
                                       </td>
                                       <td styleCode="Rrule">27.4%<br/>(17.7%, 37.0%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 52</content>
                                       </td>
                                       <td styleCode="Rrule">31.7%</td>
                                       <td styleCode="Rrule">53.5%</td>
                                       <td styleCode="Rrule">58.6%</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">21.9%<br/>(15.2%, 28.5%)<br/>
                                       </td>
                                       <td styleCode="Rrule">27.0%<br/>(20.5%, 33.6%)<br/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnote ID="t4f5">NA=Not Applicable as Study 2 was a 24-week study.</footnote>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule">
                                          <content styleCode="bold">Â ACR50</content>
                                       </td>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 12</content>
                                       </td>
                                       <td styleCode="Rrule">12.3%</td>
                                       <td styleCode="Rrule">26.5%</td>
                                       <td styleCode="Rrule">36.3%</td>
                                       <td styleCode="Rrule">13.3%</td>
                                       <td styleCode="Rrule">30.4%</td>
                                       <td styleCode="Rrule">33.2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">14.2%<br/>(8.9%, 19.6%)</td>
                                       <td styleCode="Rrule">24.1%<br/>(18.4%, 29.8%)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">17.1%<br/>(9.2%, 25.1%)</td>
                                       <td styleCode="Rrule">20.1%<br/>(12.0%, 28.3%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 24</content>
                                       </td>
                                       <td styleCode="Rrule">16.6%</td>
                                       <td styleCode="Rrule">37.0%</td>
                                       <td styleCode="Rrule">45.6%</td>
                                       <td styleCode="Rrule">18.2%</td>
                                       <td styleCode="Rrule">37.0%</td>
                                       <td styleCode="Rrule">40.8%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">20.4%<br/>(14.5%, 26.3%)<br/>
                                       </td>
                                       <td styleCode="Rrule">29.1%<br/>(23.0%, 35.1%)<br/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">18.8%<br/>(10.2%, 27.4%)<br/>
                                       </td>
                                       <td styleCode="Rrule">22.8%<br/>(14.0%, 31.6%)<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 52</content>
                                       </td>
                                       <td styleCode="Rrule">18.1%</td>
                                       <td styleCode="Rrule">40.0%</td>
                                       <td styleCode="Rrule">42.9%</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">21.9%<br/>(15.8%, 28.0%)<br/>
                                       </td>
                                       <td styleCode="Rrule">24.8%<br/>(18.7%, 30.9%)<br/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule">
                                          <content styleCode="bold">Â ACR70</content>
                                       </td>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 12</content>
                                       </td>
                                       <td styleCode="Rrule">4.0%</td>
                                       <td styleCode="Rrule">11.0%</td>
                                       <td styleCode="Rrule">17.5%</td>
                                       <td styleCode="Rrule">2.2%</td>
                                       <td styleCode="Rrule">13.8%</td>
                                       <td styleCode="Rrule">14.7%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">7.0%<br/>(3.4%, 10.6%)<br/>
                                       </td>
                                       <td styleCode="Rrule">13.5%<br/>(9.4%, 17.7%)<br/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">11.6%<br/>(6.2%, 17.0%)<br/>
                                       </td>
                                       <td styleCode="Rrule">12.5%<br/>(7.1%, 17.9%)<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 24</content>
                                       </td>
                                       <td styleCode="Rrule">7.3%</td>
                                       <td styleCode="Rrule">19.8%</td>
                                       <td styleCode="Rrule">24.8%</td>
                                       <td styleCode="Rrule">7.2%</td>
                                       <td styleCode="Rrule">19.9%</td>
                                       <td styleCode="Rrule">16.3%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">12.5%<br/>(7.8%, 17.1%)<br/>
                                       </td>
                                       <td styleCode="Rrule">17.5%<br/>(12.6%, 22.5%)<br/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">12.7%<br/>(6.1%, 19.3%)<br/>
                                       </td>
                                       <td styleCode="Rrule">9.2%<br/>(2.8%, 15.7%)<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 52</content>
                                       </td>
                                       <td styleCode="Rrule">9.0%</td>
                                       <td styleCode="Rrule">24.8%</td>
                                       <td styleCode="Rrule">26.8%</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">15.7%<br/>(10.6%, 20.8%)<br/>
                                       </td>
                                       <td styleCode="Rrule">17.8%<br/>(12.6%, 23.0%)<br/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule" valign="bottom">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule">
                                          <content styleCode="bold">Â Major clinical response<footnote>Major clinical response = ACR70 for at least 24 consecutive weeks during the 52-week period.</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                       <td styleCode="Rrule Toprule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Â Â Responders<br/>
                                       </td>
                                       <td styleCode="Rrule">3.0%</td>
                                       <td styleCode="Rrule">12.8%</td>
                                       <td styleCode="Rrule">14.8%</td>
                                       <td styleCode="Rrule">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                       <td styleCode="Rrule">NA<footnoteRef IDREF="t4f5"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Difference from placebo (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">9.7%<br/>(6.1%, 13.4%)<br/>
                                       </td>
                                       <td styleCode="Rrule">11.8%<br/>(7.9%, 15.6%)<br/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â DAS28-CRP &lt; 2.6</content>
                                          <footnote>Patients with DAS28-CRP &lt;2.6 may have active joints.</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 12</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Â Percentage of patients</td>
                                       <td styleCode="Rrule">4.8%</td>
                                       <td styleCode="Rrule">18.0%</td>
                                       <td styleCode="Rrule">23.1%</td>
                                       <td styleCode="Rrule">3.9%</td>
                                       <td styleCode="Rrule">17.1%</td>
                                       <td styleCode="Rrule">17.9%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo<br/>Â (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">13.3%<br/>(9.0%, 17.5%)</td>
                                       <td styleCode="Rrule">18.3%<br/>(13.7%, 23.0%)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">13.3%<br/>(7.3%, 19.3%)</td>
                                       <td styleCode="Rrule">14.1%<br/>(8.0%, 20.3%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Â Â Â Â Week 24</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Â Percentage of patients</td>
                                       <td styleCode="Rrule">10.1%</td>
                                       <td styleCode="Rrule">27.8%</td>
                                       <td styleCode="Rrule">34.1%</td>
                                       <td styleCode="Rrule">7.2%</td>
                                       <td styleCode="Rrule">24.9%</td>
                                       <td styleCode="Rrule">28.8%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo<br/>Â Â Â Â (95% CI)<footnoteRef IDREF="t4f3"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">17.7%<br/>(12.5%, 23.0%)</td>
                                       <td styleCode="Rrule">24.0%<br/>(18.5%, 29.5%)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">17.7%<br/>(10.5%, 24.9%)</td>
                                       <td styleCode="Rrule">21.7%<br/>(14.3%, 29.1%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The percent ACR20 response by visit in Study 1 is shown in Figure 1. A similar response curve was observed in Study 2.</paragraph>
                              <table width="100%" styleCode="Noautorules">
                                 <col width="100%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th>Figure 1: Percent of ACR20 Response by Visit for Study 1 (Adults with Moderately to Severely Active RA)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td>
                                          <renderMultiMedia referencedObject="MM1"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The results of the components of the ACR response criteria at Week 12 for Studies 1 and 2 are shown in Table 5.</paragraph>
                              <table width="90%" ID="t5">
                                 <caption>Table 5: Mean Change from Baseline in Components of ACR Score at Week 12 (Prior to Rescue) in Adults with Moderately to Severely Active RA</caption>
                                 <col width="28%" align="left" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Rrule Lrule"/>
                                       <th colspan="3" align="center" styleCode="Rrule Botrule">Study 1</th>
                                       <th colspan="3" align="center" styleCode="Rrule Botrule">Study 2</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule Lrule" valign="middle" align="center">Component means (range/units)</th>
                                       <th valign="bottom">Placebo + MTX<br/>(N=398)</th>
                                       <th valign="bottom">KEVZARA 150 mg + MTX<br/>(N=400)</th>
                                       <th styleCode="Rrule" valign="bottom">KEVZARA 200 mg + MTX<br/>(N=399)</th>
                                       <th valign="bottom">Placebo + DMARD(s)<br/>(N=181)</th>
                                       <th valign="bottom">KEVZARA 150 mg + DMARD(s)<br/>(N=181)</th>
                                       <th styleCode="Rrule" valign="bottom">KEVZARA  200 mg + DMARD(s)<br/>(N=184)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">Tender Joints (0â68)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>26.80</td>
                                       <td>27.21</td>
                                       <td styleCode="Rrule">26.50</td>
                                       <td>29.42</td>
                                       <td>27.66</td>
                                       <td styleCode="Rrule">29.55</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>16.25</td>
                                       <td>12.88</td>
                                       <td styleCode="Rrule">11.78</td>
                                       <td>19.18</td>
                                       <td>13.38</td>
                                       <td styleCode="Rrule">13.10</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td valign="middle">-10.51</td>
                                       <td valign="middle">-14.42</td>
                                       <td styleCode="Rrule" valign="middle">-14.94</td>
                                       <td valign="middle">-9.79</td>
                                       <td valign="middle">-14.11</td>
                                       <td styleCode="Rrule" valign="middle">-15.92</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">Swollen Joints (0â66)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>16.68</td>
                                       <td>16.60</td>
                                       <td styleCode="Rrule">16.77</td>
                                       <td>20.21</td>
                                       <td>19.60</td>
                                       <td styleCode="Rrule">19.97</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>9.66</td>
                                       <td>7.50</td>
                                       <td styleCode="Rrule">6.79</td>
                                       <td>12.50</td>
                                       <td>8.82</td>
                                       <td styleCode="Rrule">8.28</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-7.02</td>
                                       <td>-9.03</td>
                                       <td styleCode="Rrule">-10.12</td>
                                       <td>-7.25</td>
                                       <td>-10.77</td>
                                       <td styleCode="Rrule">-10.89</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">Pain VAS<footnote ID="t5f1">VAS=visual analog scale</footnote> (0â100 mm)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>63.71</td>
                                       <td>65.48</td>
                                       <td styleCode="Rrule">66.71</td>
                                       <td>71.57</td>
                                       <td>71.02</td>
                                       <td styleCode="Rrule">74.86</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>49.25</td>
                                       <td>41.47</td>
                                       <td styleCode="Rrule">36.93</td>
                                       <td>54.77</td>
                                       <td>43.45</td>
                                       <td styleCode="Rrule">41.66</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-14.45</td>
                                       <td>-23.73</td>
                                       <td styleCode="Rrule">-29.77</td>
                                       <td>-16.12</td>
                                       <td>-27.95</td>
                                       <td styleCode="Rrule">-32.77</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">Physician global VAS<footnoteRef IDREF="t5f1"/> (0â100 mm)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>62.86</td>
                                       <td>63.43</td>
                                       <td styleCode="Rrule">63.59</td>
                                       <td>68.39</td>
                                       <td>68.10</td>
                                       <td styleCode="Rrule">67.76</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>39.25</td>
                                       <td>31.32</td>
                                       <td styleCode="Rrule">28.47</td>
                                       <td>43.73</td>
                                       <td>33.65</td>
                                       <td styleCode="Rrule">30.18</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-23.63</td>
                                       <td>-31.85</td>
                                       <td styleCode="Rrule">-34.84</td>
                                       <td>-24.60</td>
                                       <td>-34.92</td>
                                       <td styleCode="Rrule">-36.92</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">Patient global VAS<footnoteRef IDREF="t5f1"/> (0â100 mm)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>63.70</td>
                                       <td>64.43</td>
                                       <td styleCode="Rrule">66.49</td>
                                       <td>68.77</td>
                                       <td>67.71</td>
                                       <td styleCode="Rrule">70.89</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>49.37</td>
                                       <td>41.52</td>
                                       <td styleCode="Rrule">38.05</td>
                                       <td>53.67</td>
                                       <td>41.99</td>
                                       <td styleCode="Rrule">41.74</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-13.92</td>
                                       <td>-22.88</td>
                                       <td styleCode="Rrule">-28.39</td>
                                       <td>-15.05</td>
                                       <td>-26.05</td>
                                       <td styleCode="Rrule">-28.83</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">HAQ-DI (0â3)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>1.61</td>
                                       <td>1.63</td>
                                       <td styleCode="Rrule">1.69</td>
                                       <td>1.80</td>
                                       <td>1.72</td>
                                       <td styleCode="Rrule">1.82</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>1.34</td>
                                       <td>1.15</td>
                                       <td styleCode="Rrule">1.13</td>
                                       <td>1.49</td>
                                       <td>1.23</td>
                                       <td styleCode="Rrule">1.33</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-0.27</td>
                                       <td>-0.47</td>
                                       <td styleCode="Rrule">-0.57</td>
                                       <td>-0.29</td>
                                       <td>-0.50</td>
                                       <td styleCode="Rrule">-0.49</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">
                                          <content styleCode="bold">CRP (mg/L)</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Baseline </td>
                                       <td>20.46</td>
                                       <td>22.57</td>
                                       <td styleCode="Rrule">22.23</td>
                                       <td>26.02</td>
                                       <td>23.60</td>
                                       <td styleCode="Rrule">30.77</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Week 12 </td>
                                       <td>19.61</td>
                                       <td>9.24</td>
                                       <td styleCode="Rrule">3.30</td>
                                       <td>21.72</td>
                                       <td>9.21</td>
                                       <td styleCode="Rrule">4.58</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Change from baseline</td>
                                       <td>-0.58</td>
                                       <td>-13.59</td>
                                       <td styleCode="Rrule">-18.31</td>
                                       <td>-3.39</td>
                                       <td>-14.24</td>
                                       <td styleCode="Rrule">-25.91</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250516"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4b251f49-8888-4303-ba54-9f6cc0228e83"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Radiographic Response</content>
                              </paragraph>
                              <paragraph>In Study 1, structural joint damage was assessed radiographically and expressed as the van der Heijde-modified Total Sharp Score (mTSS) and its components, the erosion score and joint space narrowing score. Radiographs of hands and feet were obtained at baseline, 24 weeks, and 52 weeks and scored independently by at least two well-trained readers who were blinded to treatment group and visit number.</paragraph>
                              <paragraph>Both doses of KEVZARA + MTX were superior to placebo + MTX in the change from baseline in mTSS over 52 weeks (see <linkHtml href="#t6">Table 6</linkHtml>). Less progression of both erosion and joint space narrowing scores over 52 weeks was reported in the KEVZARA + MTX treatment groups compared to the placebo + MTX group.</paragraph>
                              <paragraph>Treatment with KEVZARA + MTX was associated with significantly less radiographic progression of structural damage as compared with placebo + MTX. At Week 52, 55.6% of patients receiving KEVZARA 200 mg + MTX and 47.8% of patients receiving KEVZARA 150 mg + MTX had no progression of structural damage (as defined by a change in the Total Sharp Score of zero or less) compared with 38.7% of patients receiving placebo.</paragraph>
                              <table width="85%" ID="t6">
                                 <caption>Table 6: Mean Radiographic Change from Baseline at Week 52 in Study 1 in Adults with Moderately to Severely Active RA<footnote>Week 52 analysis employs linear extrapolation method to impute missing or post-rescue data</footnote>
                                 </caption>
                                 <col width="35%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2"/>
                                       <th styleCode="Rrule" colspan="3" valign="top" align="center">Study 1</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">Placebo + MTX<br/>(N=398)</th>
                                       <th styleCode="Rrule">KEVZARA  150 mg + MTX<br/>(N=400)</th>
                                       <th styleCode="Rrule">KEVZARA  200 mg + MTX<br/>(N=399)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Modified Total Sharp Score  (mTSS)</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Mean change</td>
                                       <td styleCode="Rrule">2.78</td>
                                       <td styleCode="Rrule">0.90</td>
                                       <td styleCode="Rrule">0.25</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â LS<footnote ID="t6f2">LS=least squares</footnote> mean difference (95% CI<footnote ID="t6f3">CI=confidence interval</footnote>)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-1.88 (-2.74, -1.01)</td>
                                       <td styleCode="Rrule">-2.52 (-3.38, -1.66)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Erosion score</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Mean change</td>
                                       <td styleCode="Rrule">1.46</td>
                                       <td styleCode="Rrule">0.42</td>
                                       <td styleCode="Rrule">0.05</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â LS<footnoteRef IDREF="t6f2"/> mean difference (95% CI<footnoteRef IDREF="t6f3"/>)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-1.03 (-1.53, -0.53)</td>
                                       <td styleCode="Rrule">-1.40 (-1.90, -0.90)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Joint space narrowing score</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Mean change</td>
                                       <td styleCode="Rrule">1.32</td>
                                       <td styleCode="Rrule">0.47</td>
                                       <td styleCode="Rrule">0.20</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â LS<footnoteRef IDREF="t6f2"/> mean difference (95% CI<footnoteRef IDREF="t6f3"/>)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.85 (-1.34, -0.35)</td>
                                       <td styleCode="Rrule">-1.12 (-1.61, -0.63)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b03e5018-e876-4593-a9a6-d0891762c4c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Physical Function Response</content>
                              </paragraph>
                              <paragraph>In Studies 1 and 2, physical function and disability were assessed by the Health Assessment Questionnaire Disability Index (HAQ-DI). Patients receiving KEVZARA 200 mg every two weeks + MTX/DMARD and KEVZARA 150 mg every two weeks + MTX/DMARD demonstrated greater improvement from baseline in physical function compared to placebo + MTX/DMARD at Week 16 and Week 12 in Studies 1 and 2, respectively (Table 7).</paragraph>
                              <table width="85%" ID="t7">
                                 <caption>Table 7: Physical Function in Studies 1 and 2 in Adults with Moderately to Severely Active RA</caption>
                                 <col width="16%" align="left" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <col width="14%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="3" align="center">Study 1</th>
                                       <th styleCode="Rrule" colspan="3" align="center">Study 2</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="3" align="center">Week 16</th>
                                       <th styleCode="Rrule" colspan="3" align="center">Week 12</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" align="center" valign="top">Placebo  + MTX<br/>(N=398)</th>
                                       <th styleCode="Rrule" valign="top">KEVZARA  150 mg  + MTX<br/>(N=400)</th>
                                       <th styleCode="Rrule" valign="top">KEVZARA  200 mg  + MTX<br/>(N=399)</th>
                                       <th styleCode="Rrule" valign="top">Placebo + DMARD(s)<br/>(N=181)</th>
                                       <th styleCode="Rrule" valign="top">KEVZARA 150 mg + DMARD(s)<br/>(N=181)</th>
                                       <th styleCode="Rrule" valign="top">KEVZARA 200 mg + DMARD(s)<br/>(N=184)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">HAQ-DI </content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Change from baseline</content>
                                       </td>
                                       <td styleCode="Rrule">-0.30</td>
                                       <td styleCode="Rrule">-0.54</td>
                                       <td styleCode="Rrule">-0.58</td>
                                       <td styleCode="Rrule">-0.29</td>
                                       <td styleCode="Rrule">-0.50</td>
                                       <td styleCode="Rrule">-0.49</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Difference from placebo (95% CI)<footnote>Difference in adjusted mean change from baseline compared with placebo + DMARD at Week 16 (Study 1) or Week 12 (Study 2) and 95% confidence interval for that difference.</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.24<br/>(-0.31, -0.16)</td>
                                       <td styleCode="Rrule">-0.26<br/>(-0.34, -0.18)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.20<br/>(-0.32, -0.09)</td>
                                       <td styleCode="Rrule">-0.21<br/>(-0.33, -0.10)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">% of patients with clinically meaningful improvement</content>
                                          <footnote>Change from baseline greater than 0.3 units</footnote>
                                       </td>
                                       <td styleCode="Rrule">42.5%</td>
                                       <td styleCode="Rrule">53.8%</td>
                                       <td styleCode="Rrule">57.4%</td>
                                       <td styleCode="Rrule">35.9%</td>
                                       <td styleCode="Rrule">47%</td>
                                       <td styleCode="Rrule">51.1%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="587bb4b3-545c-4f02-a028-7ab88b8a82d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Health Related Outcomes</content>
                              </paragraph>
                              <paragraph>General health status was assessed by the Short Form health survey (SF-36) in Studies 1 and 2. Patients receiving KEVZARA 200 mg every two weeks + MTX/DMARD demonstrated greater improvement from baseline compared to placebo + MTX/DMARD in the physical component summary (PCS) at Week 24, but there was no evidence of a difference between the treatment groups in the mental component summary (MCS) at Week 24. Patients receiving KEVZARA 200 mg + MTX/DMARD reported greater improvement relative to placebo in the domains of <content styleCode="italics">Physical Functioning, Role Physical, Bodily Pain, General Health Perception, Vitality, Social Functioning and Mental Health,</content> but not in the <content styleCode="italics">Role Emotional</content> domain<content styleCode="italics">.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="7a9fcd97-93a7-479f-9d74-e35ae7e4d5c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Polymyalgia Rheumatica</title>
                     <text>
                        <paragraph>The efficacy and safety of KEVZARA in PMR were assessed in a randomized, double-blind, placebo-controlled, 52-week, multicenter study (Study 3) (NCT03600818) in adults with PMR diagnosed according to American College of Rheumatology/European Union League against Rheumatism (ACR/EULAR) classification criteria. Patients had at least one episode of unequivocal PMR flare while attempting to taper corticosteroids.</paragraph>
                        <paragraph>In Study 3, patients with active PMR were randomized to receive KEVZARA 200 mg every two weeks with a pre-defined 14-week taper of prednisone (n= 60) or placebo every two weeks with a pre-defined 52-week taper of prednisone (n=58). One participant was randomized but not treated in the KEVZARA 200 mg arm. Patients experiencing a disease flare or unable to adhere to the assigned prednisone tapering schedule could receive corticosteroids as rescue therapy.</paragraph>
                        <paragraph>The primary endpoint was the proportion of patients with sustained remission at Week 52. Sustained remission was defined as achievement of disease remission no later than Week 12, absence of disease flare from Week 12 through Week 52, sustained reduction of CRP (to &lt;10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52. An additional endpoint was total cumulative corticosteroid dose over 52 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                     <component>
                        <section>
                           <id root="1e132323-e9e9-44e4-9135-0abfcc90908a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Response</content>
                              </paragraph>
                              <paragraph>The proportion of participants achieving sustained remission at Week 52 was higher in the KEVZARA arm compared to the placebo arm; this difference was statistically significant. At 52 weeks, a higher proportion of patients in the KEVZARA arm achieved each component of the sustained remission endpoint compared to the placebo. An analysis was conducted that removed all acute phase reactants (CRP and ESR) criteria from the definition of the sustained remission, given sarilumab's direct impact on acute phase reactants. The results of this analysis were consistent with the primary analysis (see <linkHtml href="#Table8">Table 8</linkHtml>).</paragraph>
                              <table width="85%" ID="Table8">
                                 <caption>Table 8 Clinical Response in Placebo-Controlled Study 3 in Adults with Active PMR</caption>
                                 <col width="2%" align="left" valign="top"/>
                                 <col width="58%" align="left" valign="top"/>
                                 <col width="15%" align="left" valign="top"/>
                                 <col width="25%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule">Placebo<br/> (N=58)</th>
                                       <th styleCode="Rrule">KEVZARA<br/> (N=60)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Sustained remission at Week 52</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Number of patients with sustained remission, n (%)</td>
                                       <td styleCode="Rrule">6 (10.3)</td>
                                       <td styleCode="Rrule">17 (28.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Proportion difference (95% CI) vs. placebo</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">18.0 (4.2, 31.8; p=0.0193)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Components of sustained remission at Week 52</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Absence of signs and symptoms and CRP &lt; 10 mg/L (disease remission<footnote>Disease remission is defined as the resolution of signs and symptoms of PMR, and normalization of CRP (&lt;10 mg/L).</footnote>) no later than Week 12, n (%)</td>
                                       <td styleCode="Rrule">22 (37.9)</td>
                                       <td styleCode="Rrule">28 (46.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Absence of disease flare<footnote>Flare is defined as recurrence of signs and symptoms attributable to active PMR requiring an increase in corticosteroid dose, or elevation of ESR attributable to active PMR plus an increase in corticosteroid dose.</footnote> from Week 12 through Week 52, n (%)</td>
                                       <td styleCode="Rrule">19 (32.8)</td>
                                       <td styleCode="Rrule">33 (55.0)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Sustained reduction of CRP (&lt;10 mg/L) from Week 12 through Week 52, n (%)</td>
                                       <td styleCode="Rrule">26 (44.8)</td>
                                       <td styleCode="Rrule">40 (66.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Successful adherence to prednisone taper from Week 12 through Week 52, n (%)</td>
                                       <td styleCode="Rrule">14 (24.1)</td>
                                       <td styleCode="Rrule">30 (50.0)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="4">
                                          <content styleCode="bold">Sensitivity analysis removing acute phase reactants (CRP and ESR) from sustained remission at Week 52</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Number of patients with sustained remission, n (%)</td>
                                       <td styleCode="Rrule">8 (13.8)</td>
                                       <td styleCode="Rrule">19 (31.7)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">Proportion difference (95% CI) for sarilumab vs. placebo</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">17.9 (3.1, 32.6)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a3d00106-6fb3-488d-8d97-6364f62f7073"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect on Concomitant Corticosteroid Use</content>
                              </paragraph>
                              <paragraph>The total actual cumulative corticosteroid dose included all corticosteroids taken during the study (i.e., prednisone taper regimen per protocol, add-on prednisone prior to Week 12, corticosteroid use due to rescue, or corticosteroid use during the treatment period to manage an adverse reaction not related to PMR). The total actual cumulative prednisone equivalent corticosteroid dose was lower in the KEVZARA arm (mean [SD] 1039.5 [612.2] mg and median 777 mg) relative to the placebo arm (mean [SD] 2235.8 [839.4] mg and median 2044 mg).</paragraph>
                           </text>
                           <effectiveTime value="20250516"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="0bcd1827-5a5c-4b9c-a03e-757742056379"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Polyarticular Juvenile Idiopathic Arthritis (pJIA)</title>
                     <text>
                        <paragraph>Supportive efficacy and safety data were provided from Study 4, which was a multicenter, open-label, two-phase study in patients aged 2 to 17 years of age with polyarticular juvenile idiopathic arthritis (pJIA) diagnosed according to American College Rheumatology (ACR) classification criteria who had an inadequate response to current therapy. This study was divided into a dose range finding portion and a confirmatory portion. Three doses were investigated in the 12-week core treatment phase of the dose range finding portion. Following the dose selection, patients were enrolled to receive the recommended dose [3 mg/kg every 2 weeks (q2w) in 42 patients weighing â¥30 kg (Group A) and 4 mg/kg q2w in 31 patients weighing â¥10 kg and &lt;30 kg (Group B)]. A total of 101 patients were treated, including 73 patients who received the recommended dose regimen from baseline and 20 patients who had their dose switched to the recommended dose during the study. Of the 73 patients who received the recommended dose throughout treatment, baseline mean disease duration was 2.48 years and a JADAS-27 score of 22.73. At baseline, 84.9% of patients had received at least one conventional DMARD (mainly methotrexate), 13.7% received systemic glucocorticoids, and 19.2% had prior treatment with biological DMARDs (mainly TNF antagonists). The patients treated had subtypes of JIA that, at disease onset, included rheumatoid factor positive (17.8%), negative polyarticular JIA (65.8%), or extended oligoarticular JIA (16.4%).</paragraph>
                        <paragraph>Use of KEVZARA in pediatric patients with pJIA is supported by evidence from adequate and well-controlled studies of KEVZARA in adults with RA, pharmacokinetic data from adult patients with RA, and pharmacokinetic (PK) comparability from Study 4 <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="f062436a-d828-409e-89a2-61af0091b766"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>KEVZARA (sarilumab) injection is supplied as a clear and colorless to pale yellow solution in single-dose pre-filled syringes, and single-dose pre-filled pens.</paragraph>
                  <table width="75%">
                     <col width="33%" align="center" valign="top"/>
                     <col width="34%" align="center" valign="top"/>
                     <col width="33%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" align="center">Strength</th>
                           <th styleCode="Rrule">Package Size</th>
                           <th styleCode="Rrule" align="center">NDC Number</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">150 mg/1.14 mL</td>
                           <td styleCode="Rrule">2 syringes per pack</td>
                           <td styleCode="Rrule">0024-5908-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">200 mg/1.14 mL</td>
                           <td styleCode="Rrule">2 syringes per pack</td>
                           <td styleCode="Rrule">0024-5910-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="75%">
                     <col width="33%" align="center" valign="top"/>
                     <col width="34%" align="center" valign="top"/>
                     <col width="33%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Strength</th>
                           <th styleCode="Rrule">Package Size</th>
                           <th styleCode="Rrule">NDC Number</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">150 mg/1.14 mL</td>
                           <td styleCode="Rrule">2 pre-filled pens per pack</td>
                           <td styleCode="Rrule">0024-5920-01</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">200 mg/1.14 mL</td>
                           <td styleCode="Rrule">2 pre-filled pens per pack</td>
                           <td styleCode="Rrule">0024-5922-01</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <section>
                     <id root="dc89457d-1893-45ab-b51f-5970d8cc3164"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage and Stability</content>
                        </paragraph>
                        <paragraph>Refrigerate at 36Â°F to 46Â°F (2Â°C to 8Â°C) in original carton to protect from light. Do not freeze. Do not shake.</paragraph>
                        <paragraph>If needed, patients/caregivers may store KEVZARA at room temperature up to 77Â°F (25Â°C) up to 14 days in the outer carton. Do not store above 77Â°F (25Â°C). After removal from the refrigerator, use KEVZARA within 14 days or discard.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ebef7672-2c06-4663-952b-a919d0d2ba8e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patients to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <section>
                     <id root="1c8991fa-0149-424a-8426-8fb1ceb33c14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Infections</content>
                        </paragraph>
                        <paragraph>Inform patients that KEVZARA may lower their resistance to infections. Instruct patients to contact their physician immediately when symptoms suggesting infection appear, to ensure rapid evaluation and appropriate treatment <content styleCode="italics">[see <linkHtml href="#S5.1">Warning and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3b514121-4fe9-4b6c-ba86-478b21106c80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Gastrointestinal Perforation</content>
                        </paragraph>
                        <paragraph>Inform patients that some patients, particularly those also taking NSAIDS, and/or steroids, have had tears (perforations) of the stomach or intestines. Inform patients that gastrointestinal perforations have been reported in KEVZARA-treated patients in clinical studies, primarily as a complication of diverticulitis. Instruct patients to contact their physician immediately when symptoms of severe, persistent abdominal pain appear to ensure rapid evaluation and appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8a0d9f6b-022d-42e7-9679-4e92537f3d91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Hypersensitivity and Serious Allergic Reaction</content>
                        </paragraph>
                        <paragraph>Assess patient suitability for home use for SC injection. Inform patients that some patients who have been treated with KEVZARA have developed serious allergic reactions. Advise patients to seek immediate medical attention if they experience any symptom of serious allergic reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="fa3f74cf-01e3-4589-b86c-2b7bfaf49c64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Instruction on Injection Technique</content>
                        </paragraph>
                        <paragraph>Instruct patients and caregivers to read the Instructions for Use before the patient starts using KEVZARA, and each time the patient gets a refill as there may be new information they need to know.</paragraph>
                        <paragraph>Provide guidance to patients and caregivers on proper subcutaneous injection technique, including aseptic technique, and how to use the pre-filled syringe or pre-filled pen correctly (<content styleCode="italics">see <linkHtml href="#ifu">Instructions for Use</linkHtml>
                           </content>).</paragraph>
                        <paragraph>The pre-filled syringe or pre-filled pen should be left at room temperature for 30 minutes or 60 minutes respectively (see the<linkHtml href="#ifu"> Instructions for Use</linkHtml>)  prior to use. The syringe or pen should be used within 14 days after being taken out of the refrigerator. A puncture-resistant container should be used to dispose the used pre-filled syringes or pre-filled pens and should be kept out of the reach of children. Instruct patients or caregivers in the technique as well as proper pre-filled syringe or pre-filled pen disposal, and caution against reuse of these items.</paragraph>
                     </text>
                     <effectiveTime value="20250516"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="662383c1-8aac-4285-89fd-944b04d6f2fd"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold italics">REGENERON</content>
                     <br/>
                     <content styleCode="bold">sanofi</content>
                  </paragraph>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>U.S. License No. 1752</paragraph>
                  <paragraph>Marketed by:</paragraph>
                  <paragraph>sanofi-aventis U.S. LLC (Morristown, NJ 07960) and</paragraph>
                  <paragraph>Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)</paragraph>
                  <paragraph>For patent information: www.kevzara-patents.com</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology</paragraph>
                  <paragraph>Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC</paragraph>
               </text>
               <effectiveTime value="20250516"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fdedca96-439a-40df-97db-0aa816998a79"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="7%" align="left" valign="top"/>
                     <col width="38%" align="left" valign="top"/>
                     <col width="35%" align="left" valign="top"/>
                     <col width="20%" align="right" valign="top"/>
                     <thead>
                        <tr>
                           <th colspan="4" align="center" valign="top" styleCode="Lrule Rrule">MEDICATION GUIDE<br/>KEVZARA<sup>Â®</sup> (KEV-za-ra)<br/>(sarilumab)<br/>injection, for subcutaneous use</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left" valign="top">This Medication Guide has been approved by the U.S. Food and Drug Administration</td>
                           <td>Revised: May 2025Â Â Â Â Â </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="important">What is the most important information I should know about KEVZARA?<br/>KEVZARA can cause serious side effects including:</content>
                              <list listType="unordered">
                                 <item>
                                    <caption styleCode="bold">1.</caption>
                                    <content styleCode="bold">Serious Infections.</content> KEVZARA is a prescription medicine that affects your immune system. KEVZARA can lower the ability of your immune system to fight infections. Some people have serious infections while using KEVZARA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.<br/>Your healthcare provider should test you or your child for TB before starting KEVZARA.<list listType="unordered" styleCode="disc">
                                       <item>Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with KEVZARA.</item>
                                    </list>You should not start using KEVZARA if you have any kind of infection unless your healthcare provider says it is okay.<br/>Before starting KEVZARA, tell your healthcare provider if you:<list listType="unordered" styleCode="disc">
                                       <item>think you have an infection or have signs or symptoms of an infection, with or without a fever, such as: </item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>sweats or chills</item>
                                 <item>muscle aches</item>
                                 <item>cough</item>
                                 <item>shortness of breath</item>
                                 <item>blood in your phlegm</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>weight loss</item>
                                 <item>warm, red or painful skin or sores on your body</item>
                                 <item>diarrhea or stomach pain</item>
                                 <item>burning when you urinate or urinating more often than normal</item>
                                 <item>feeling very tired</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <caption/>
                                    <list listType="unordered" styleCode="disc">
                                       <item>are being treated for an infection.</item>
                                       <item>get a lot of infections or have infections that keep coming back.</item>
                                       <item>have diabetes, HIV, or a weak immune system. People with these conditions have a higher chance of getting infections.</item>
                                       <item>have TB, or have been in close contact with someone with TB.</item>
                                       <item>live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance of getting certain fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen more often or become more severe if you use KEVZARA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.</item>
                                       <item>have or have had hepatitis.</item>
                                    </list>After starting KEVZARA, call your healthcare provider right away if you have any symptoms of an infection.</item>
                                 <item>
                                    <caption styleCode="bold">2.</caption>
                                    <content styleCode="bold">Changes in certain laboratory test results. </content>
                                    <br/>Your  or your child's healthcare provider should do blood tests before you start KEVZARA, 4 to 8 weeks after starting KEVZARA, and then every 3 months during treatment to check for:<list listType="unordered" styleCode="disc">
                                       <item>
                                          <content styleCode="bold">low neutrophil count</content>. Neutrophils are white blood cells that help the body fight off bacterial infections. A low neutrophil count is common with KEVZARA, and can be severe.</item>
                                       <item>
                                          <content styleCode="bold">low platelet count</content>. Platelets are blood cells that help with blood clotting and stop bleeding.</item>
                                       <item>
                                          <content styleCode="bold">increase in certain liver function tests</content>. An increase in certain liver function tests is common with KEVZARA, and can be severe.</item>
                                    </list>Your healthcare provider may not prescribe KEVZARA if your neutrophil or platelet counts are too low, or your liver function tests are too high. Your healthcare provider may stop your KEVZARA treatment for a period of time or change your dose if needed because of changes in these blood test results.<br/>Your  or your child's healthcare provider should do blood tests 4 to 8 weeks after starting KEVZARA and then every 6 months during treatment to check for an:<list listType="unordered" styleCode="disc">
                                       <item>
                                          <content styleCode="bold">increase in blood cholesterol levels</content>.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption styleCode="bold">3.</caption>
                                    <content styleCode="bold">Tears (perforation) of the stomach or intestines.</content> Tell your healthcare provider if you have had a condition known as diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people using KEVZARA get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Call your healthcare provider right away if you have fever and stomach (abdominal) pain that does not go away.</item>
                                 <item>
                                    <caption styleCode="bold">4.</caption>
                                    <content styleCode="bold">Cancer.</content> KEVZARA may increase your risk of certain cancers by changing the way your immune system works. Tell your healthcare provider if you have ever had any type of cancer.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">See "<linkHtml href="#effects">What are the possible side effects of KEVZARA?</linkHtml>" for more information about side effects.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is KEVZARA?</content>
                              <br/>KEVZARA is an injectable prescription medicine called an interleukin-6 (IL-6) receptor blocker. KEVZARA is used: 										<list styleCode="disc" listType="unordered">
                                 <item>To treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well or could not be tolerated.</item>
                                 <item>To treat adults with polymyalgia rheumatica (PMR) after corticosteroids have been used and did not work well or when a slow decrease in the dose of corticosteroids (taper) cannot be tolerated.</item>
                                 <item>To treat people with active polyarticular juvenile idiopathic arthritis (pJIA) who weigh 63 kg or more.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">It is not known if KEVZARA is safe and effective in children with pJIA under 2 years of age.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Who should not use KEVZARA?</content>
                              <br/>Do not use KEVZARA if you or your child are allergic to sarilumab or any of the ingredients in KEVZARA. See the end of this Medication Guide for a complete list of ingredients in KEVZARA.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before you or your child use KEVZARA, talk to your healthcare provider about all of your medical conditions, including if you or your child: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have an infection. See "<content styleCode="bold">
                                       <linkHtml href="#important">What is the most important information I should know about KEVZARA?</linkHtml>
                                    </content>"</item>
                                 <item>have liver problems.</item>
                                 <item>have had stomach (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines.</item>
                                 <item>have recently received or are scheduled to receive a vaccine. People who take KEVZARA should not receive live vaccines.<list styleCode="circle" listType="unordered">
                                       <item>All vaccines should be brought up-to-date before starting KEVZARA, unless urgent treatment initiation is required.</item>
                                    </list>
                                 </item>
                                 <item>plan to have surgery or a medical procedure. </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if KEVZARA will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if KEVZARA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use KEVZARA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you or your child take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br/>
                                 <content styleCode="bold">Especially tell your healthcare provider if you or your child use</content>:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>any other medicines to treat your RA, PMR or pJIA. You should not take rituximab (Rituxan<sup>Â®</sup>), etanercept (Enbrel<sup>Â®</sup>), infliximab (Remicade<sup>Â®</sup>), anakinra (Kineret<sup>Â®</sup>), adalimumab (Humira<sup>Â®</sup>), abatacept (Orencia<sup>Â®</sup>), certolizumab (Cimzia<sup>Â®</sup>), golimumab (Simponi<sup>Â®</sup>), tocilizumab (Actemra<sup>Â®</sup>), or tofacitinib (Xeljanz<sup>Â®</sup>) while you are using KEVZARA. Using KEVZARA with these medicines may increase your risk of infection. </item>
                                 <item>medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these. </item>
                              </list>
                              <paragraph>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I use KEVZARA? </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">See the detailed Instructions for Use that comes with this Medication Guide for instructions about the right way to prepare and give your KEVZARA injections at home. </content>
                                 </item>
                                 <item>KEVZARA is given as an injection under the skin (subcutaneous injection). </item>
                                 <item>KEVZARA is available as a single-use pre-filled syringe and a single-use pre-filled pen. Your healthcare provider will prescribe the dose and type of KEVZARA that is best for you or your child.</item>
                                 <item>If your healthcare provider decides that you or a caregiver can give the injections of KEVZARA at home using the pre-filled pen or pre-filled syringe, you or your caregiver should receive training on the right way to prepare and inject KEVZARA. Do not try to inject KEVZARA until you have been shown the right way to give the injections by your healthcare provider. </item>
                                 <item>Inject 1 dose of KEVZARA every 2 weeks.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="effects">What are the possible side effects of KEVZARA? <br/>KEVZARA can cause serious side effects, including: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">See "<linkHtml href="#important">What is the most important information I should know about KEVZARA?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Serious allergic reactions.</content> Serious allergic reactions can happen with KEVZARA. Get medical attention right away if you or your child have any of the following signs of a serious allergic reaction:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>shortness of breath or trouble breathing</item>
                                 <item>swelling of the lips, tongue, or face</item>
                                 <item>chest pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>feeling dizzy or faint</item>
                                 <item>moderate or severe stomach (abdominal) pain or vomiting</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Common side effects of KEVZARA include: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>injection site redness</item>
                                 <item>injection site itching</item>
                                 <item>upper respiratory tract infection </item>
                                 <item>urinary tract infection</item>
                                 <item>nasal congestion, sore throat, and runny nose </item>
                              </list>
                              <paragraph>These are not all of the possible side effects of KEVZARA. <br/>
                                 <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088</content>. <br/>You may also report side effects to sanofi-aventis at 1-800-633-1610.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store KEVZARA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store KEVZARA in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). Store KEVZARA in the original carton until use to protect it from light.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze KEVZARA. </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> shake KEVZARA.</item>
                                 <item>KEVZARA may be stored at room temperature up to 77Â°F (25Â°C) for up to <content styleCode="bold">14</content> days in the original outer carton. </item>
                                 <item>Throw away KEVZARA if it has been kept at room temperature and not been used within <content styleCode="bold">14</content> days.</item>
                              </list>
                              <content styleCode="bold">Keep KEVZARA and all medicines out of the reach of children</content>. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">General Information about the safe and effective use of KEVZARA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use KEVZARA for a condition for which it was not prescribed. Do not give KEVZARA to other people, even if they have the same symptoms you have. It may harm them.<br/>You can ask your healthcare provider or pharmacist for information about KEVZARA that is written for health professionals. </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in KEVZARA? <br/>Active Ingredient</content>: sarilumab<br/>
                              <content styleCode="bold">Inactive Ingredients</content>: arginine, histidine, polysorbate 20, sucrose, and Water for Injection, USP.<br/>
                              <content styleCode="bold">
                                 <content styleCode="italics">REGENERON</content>
                                 <br/> sanofi</content>
                              <br/>Manufactured by: sanofi-aventis U.S. LLC Morristown, NJ 07960, A SANOFI COMPANY U.S. License # 1752. Marketed by: sanofi-aventis U.S. LLC (Morristown, NJ 07960) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591) KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC<br/>For more information, go to www.KEVZARA.com or call 1-844-KEVZARA (1-844-538-9272).</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250516"/>
            </section>
         </component>
         <component>
            <section ID="ifu">
               <id root="0bd75ddf-111f-48c7-bdbb-1cecec195703"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use<br/>KEVZARA<sup>Â®</sup> (KEV-za-ra)<br/>(sarilumab)<br/>injection, for subcutaneous use<br/>Single-dose Pre-filled Syringe (150 mg/1.14 mL)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Important information:</content>
                  </paragraph>
                  <paragraph>KEVZARA is available as a single-dose pre-filled syringe (called "syringe" in these instructions). The pre-filled syringe contains 150 mg of KEVZARA for injection under the skin (subcutaneous injection) 1 time every 2 weeks.</paragraph>
                  <paragraph>Do not try to inject KEVZARA until you have been shown the right way to give the injections by your healthcare provider.</paragraph>
                  <table width="80%">
                     <colgroup>
                        <col width="50%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Lrule Rrule" align="center">Do</th>
                           <th styleCode="Rrule" align="center">Do not</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td styleCode="Lrule Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read all of the instructions carefully before using the syringe.</item>
                                 <item>Keep unused syringes in the original carton and store in the refrigerator between 36Â°F and 46Â°F (2Â°C and 8Â°C).</item>
                                 <item>Keep the carton in an insulated bag with an ice pack when traveling.</item>
                                 <item>Let the syringe warm up at room temperature for at least 30 minutes before using.</item>
                                 <item>Use the syringe within <content styleCode="bold">14</content> days after taking it out of the refrigerator or insulated bag.</item>
                                 <item>Keep the syringe and all medicines out of the reach of children.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not use the syringe if it has been damaged or the needle cap is missing or not attached. Return the syringe and the package it came in to your pharmacy.</item>
                                 <item>Do not remove the needle cap until just before you are ready to inject.</item>
                                 <item>Do not touch the needle.</item>
                                 <item>Do not re-use the syringe or try to put the cap back on the syringe.</item>
                                 <item>Do not freeze or heat up the syringe.</item>
                                 <item>Do not expose the syringe to direct sunlight.</item>
                                 <item>Do not inject through your clothes.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Keep these instructions for future use.</paragraph>
                  <paragraph>If you have any further questions, ask your healthcare provider or call 1-844-KEVZARA (1-844-538-9272).</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEVZARA pre-filled syringe parts</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1a"/>
                  <paragraph>
                     <content styleCode="bold">What you will need for your injection:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>A new KEVZARA 150 mg/1.14 mL pre-filled syringe</item>
                     <item>Alcohol wipe</item>
                     <item>Cotton ball or gauze</item>
                     <item>Sharps disposal container. See "<content styleCode="bold">
                           <linkHtml href="#dispose_syringe">How should I dispose of (throw away) KEVZARA pre-filled syringes?</linkHtml>
                        </content>" at the end of this Instructions for Use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step A: Get ready for an injection</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Prepare all of the equipment you will need on a clean, flat working surface.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take 1 syringe out of the package by holding the middle of the syringe body. <content styleCode="bold">Do not</content> hold the syringe by the plunger, finger grip or needle cap. <content styleCode="bold">Do not</content> pull off the needle cap until you are ready to inject.</item>
                                 <item>Keep the remaining syringe in the carton in the refrigerator.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1b"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Look at the label.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check that you have the correct medicine and the correct dose.</item>
                                 <item>Check the expiration date.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the syringe if the expiration date has passed.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1c"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Look at the medicine.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check to see if the liquid in the syringe is clear and colorless to pale yellow.</item>
                                 <item>You may see air bubbles. This is normal.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject if the liquid is cloudy, discolored or contains particles. Safely dispose of the syringe in a sharps container and get a new one.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1d"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left"/>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Lay the syringe on a flat surface and allow it to warm up at room temperature for at least 30 minutes.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Using the syringe at room temperature may make the injection more comfortable.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the syringe if it has been out of the refrigerator for more than <content styleCode="bold">14</content> days.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> try to warm the syringe in any other way.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1e"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Select the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You can inject into the front of your thigh or your belly (abdomen), but not the area 2 inches (5 cm) around your belly button (navel).</item>
                                 <item>
                                    <content styleCode="bold">If somebody else gives you the injection, you can also use the upper arm</content>.</item>
                                 <item>Change the injection site each time you inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is tender, damaged or has bruises or scars.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1f"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Prepare the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Wash your hands.</item>
                                 <item>Clean the skin at the injection site with an alcohol wipe and let it air dry before injecting.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the injection site again before the injection.</item>
                              </list>
                           </td>
                           <td align="center"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step B: Give the injection </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Complete Step B after completing all steps in Step A "Get ready for an injection".</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Pull off the needle cap.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the syringe in the middle of the syringe body with the needle pointing away from you.</item>
                                 <item>Keep your hand away from the plunger.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> get rid of any air bubbles in the syringe.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> pull off the needle cap until you are ready to inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1g"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Pinch the skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use your thumb and first (index) finger to pinch a fold of skin at the cleaned injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1h"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Insert the needle into the fold of skin at about a 45 degree angle.</content>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1i"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Push the plunger down.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly push the plunger down as far as it will go until the syringe is empty.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1j"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Before you remove the needle, check that the syringe is empty.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Pull the needle out at the same angle as inserted.</item>
                                 <item>If you see any blood at the injection site, press a cotton ball or gauze on the injection site.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1k"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Dispose of the syringe.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The KEVZARA syringe should not be reused.</item>
                                 <item>Put the used syringe into your FDA-cleared sharps disposal container or a puncture resistant container (see "<content styleCode="bold">
                                       <linkHtml href="#dispose_syringe">How should I dispose of (throw away) KEVZARA pre-filled syringes?</linkHtml>
                                    </content>").</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1m"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold" ID="dispose_syringe">How should I dispose of (throw away) KEVZARA pre-filled syringes?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put the used syringe in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the syringe in your household trash.</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Circle">
                           <item>made of a heavy-duty plastic,</item>
                           <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>upright and stable during use,</item>
                           <item>leak-resistant, and</item>
                           <item>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</item>
                     <item>
                        <content styleCode="bold">Do not</content> reuse the syringe.</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important:</content> Always keep the sharps disposal container out of the reach of children.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">REGENERON</content>
                        <br/>sanofi</content>
                  </paragraph>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>U.S. License # 1752</paragraph>
                  <paragraph>Marketed by: sanofi-aventis U.S. LLC (Morristown, NJ 07960)<br/>and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology<br/>Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>Issued: May 2025</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM1a">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1b">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1c">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1d">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1e">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1f">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1g">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01g.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1h">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01h.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1i">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01i.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1j">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01j.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1k">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01k.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1m">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01m.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="49e53190-dac3-4ead-8c01-f7fb1d59b7e6"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use<br/>KEVZARA<sup>Â®</sup> (KEV-za-ra)<br/>(sarilumab)<br/>injection, for subcutaneous use<br/>Single-dose Pre-filled Syringe (200 mg/1.14 mL)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Important information:</content>
                  </paragraph>
                  <paragraph>KEVZARA is available as a single-dose pre-filled syringe (called "syringe" in these instructions). The pre-filled syringe contains 200 mg of KEVZARA for injection under the skin (subcutaneous injection) 1 time every 2 weeks.</paragraph>
                  <paragraph>Do not try to inject KEVZARA until you have been shown the right way to give the injections by your healthcare provider.</paragraph>
                  <table width="80%">
                     <colgroup>
                        <col width="50%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Lrule Rrule" align="center">Do</th>
                           <th styleCode="Rrule" align="center">Do not</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td styleCode="Lrule Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read all of the instructions carefully before using the syringe.</item>
                                 <item>Keep unused syringes in the original carton and store in the refrigerator between 36Â°F and 46Â°F (2Â°C and 8Â°C).</item>
                                 <item>Keep the carton in an insulated bag with an ice pack when traveling.</item>
                                 <item>Let the syringe warm up at room temperature for at least 30 minutes before using.</item>
                                 <item>Use the syringe within <content styleCode="bold">14</content> days after taking it out of the refrigerator or insulated bag.</item>
                                 <item>Keep the syringe and all medicines out of the reach of children.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not use the syringe if it has been damaged or the needle cap is missing or not attached. Return the syringe and the package it came in to your pharmacy.</item>
                                 <item>Do not remove the needle cap until just before you are ready to inject.</item>
                                 <item>Do not touch the needle.</item>
                                 <item>Do not re-use the syringe or try to put the cap back on the syringe.</item>
                                 <item>Do not freeze or heat up the syringe.</item>
                                 <item>Do not expose the syringe to direct sunlight.</item>
                                 <item>Do not inject through your clothes.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Keep these instructions for future use.</paragraph>
                  <paragraph>If you have any further questions, ask your healthcare provider or call 1-844-KEVZARA (1-844-538-9272).</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEVZARA pre-filled syringe parts</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1n"/>
                  <paragraph>
                     <content styleCode="bold">What you will need for your injection:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>A new KEVZARA 200 mg/1.14 mL pre-filled syringe</item>
                     <item>Alcohol wipe</item>
                     <item>Cotton ball or gauze</item>
                     <item>Sharps disposal container. See "<content styleCode="bold">
                           <linkHtml href="#dispose_syringe2">How should I dispose of (throw away) KEVZARA pre-filled syringes?</linkHtml>
                        </content>" at the end of this Instructions for Use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step A: Get ready for an injection</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Prepare all of the equipment you will need on a clean, flat working surface.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take 1 syringe out of the package by holding the middle of the syringe body. <content styleCode="bold">Do not</content> hold the syringe by the plunger, finger grip or needle cap. <content styleCode="bold">Do not</content> pull off the needle cap until you are ready to inject.</item>
                                 <item>Keep the remaining syringe in the carton in the refrigerator.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1o"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Look at the label.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check that you have the correct medicine and the correct dose.</item>
                                 <item>Check the expiration date.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the syringe if the expiration date has passed.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1p"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Look at the medicine.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check to see if the liquid in the syringe is clear and colorless to pale yellow.</item>
                                 <item>You may see air bubbles. This is normal.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject if the liquid is cloudy, discolored or contains particles. Safely dispose of the syringe in a sharps container and get a new one.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1q"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Lay the syringe on a flat surface and allow it to warm up at room temperature for at least 30 minutes.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Using the syringe at room temperature may make the injection more comfortable.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the syringe if it has been out of the refrigerator for more than 14 days.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> try to warm the syringe in any other way.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1r"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Select the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You can inject into the front of your thigh or your belly (abdomen), but not the area 2 inches (5 cm) around your belly button (navel).</item>
                                 <item>
                                    <content styleCode="bold">If somebody else gives you the injection, you can also use the upper arm</content>.</item>
                                 <item>Change the injection site each time you inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is tender, damaged or has bruises or scars.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1s"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Prepare the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Wash your hands.</item>
                                 <item>Clean the skin at the injection site with an alcohol wipe and let it air dry before injecting.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the injection site again before the injection.</item>
                              </list>
                           </td>
                           <td align="center"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step B: Give the injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Complete Step B after completing all steps in Step A "Get ready for an injection"</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Pull off the needle cap.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the syringe in the middle of the syringe body with the needle pointing away from you.</item>
                                 <item>Keep your hand away from the plunger.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> get rid of any air bubbles in the syringe.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> pull off the needle cap until you are ready to inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1t"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Pinch the skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use your thumb and first (index) finger to pinch a fold of skin at the cleaned injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1u"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Insert the needle into the fold of skin at about a 45 degree angle.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left"/>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1v"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Push the plunger down.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly push the plunger down as far as it will go until the syringe is empty.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1w"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Before you remove the needle, check that the syringe is empty.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Pull the needle out at the same angle as inserted.</item>
                                 <item>If you see any blood at the injection site, press a cotton ball or gauze on the site.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1x"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Dispose of the syringe.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The KEVZARA syringe should not be reused.</item>
                                 <item>Put the used syringe into your FDA-cleared sharps disposal container of a puncture resistant container (see "<content styleCode="bold">
                                       <linkHtml href="#dispose_syringe2">How should I dispose of (throw away) KEVZARA pre-filled syringes?</linkHtml>
                                    </content>").</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM1y"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold" ID="dispose_syringe2">How should I dispose of (throw away) KEVZARA pre-filled syringes?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put the used syringe in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the syringe in your household trash.</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Circle">
                           <item>made of a heavy-duty plastic,</item>
                           <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>upright and stable during use,</item>
                           <item>leak-resistant, and</item>
                           <item>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</item>
                     <item>
                        <content styleCode="bold">Do not</content> reuse the syringe.</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important:</content> Always keep the sharps disposal container out of the reach of children.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">REGENERON</content>
                        <br/>sanofi</content>
                  </paragraph>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>U.S. License # 1752</paragraph>
                  <paragraph>Marketed by: sanofi-aventis U.S. LLC, (Morristown, NJ 07960)<br/>and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology<br/>Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>Issued: May 2025</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM1n">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01n.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1o">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01o.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1p">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01p.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1q">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01q.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1r">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01r.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1s">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1t">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01t.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1u">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01u.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1v">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01v.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1w">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01w.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1x">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01x.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM1y">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-01y.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c34a7aca-7eba-4653-aae5-7d8549eef9ab"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use<br/>KEVZARA<sup>Â®</sup> (KEV-za-ra)<br/>(sarilumab)<br/>injection, for subcutaneous use<br/>Single-dose pre-filled pen (150 mg/1.14 mL)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Important information:</content>
                  </paragraph>
                  <paragraph>KEVZARA is available as a single-dose pre-filled pen (called "pen" in these instructions). The pre-filled pen contains 150 mg of KEVZARA for injection under the skin (subcutaneous injection) 1 time every 2 weeks.</paragraph>
                  <paragraph>Do not try to inject KEVZARA until you have been shown the right way to give the injections by your healthcare provider.</paragraph>
                  <table width="80%">
                     <colgroup>
                        <col width="50%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Lrule Rrule" align="center">Do</th>
                           <th styleCode="Rrule" align="center">Do not</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td styleCode="Lrule Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read all of the instructions carefully before using the pre-filled pen.</item>
                                 <item>Keep unused pens in the original carton and store in the refrigerator between 36Â°F and 46Â°F (2Â°C and 8Â°C).</item>
                                 <item>Keep the carton in an insulated bag with an ice pack when traveling.</item>
                                 <item>Let the pen warm up at room temperature for at least 60 minutes before using.</item>
                                 <item>Use the pen within <content styleCode="bold">14</content> days after taking it out of the refrigerator or insulated bag.</item>
                                 <item>Keep the pen and all medicines out of the reach of children.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not use the pre-filled pen if it has been damaged or the orange cap is missing or not attached. Return the pen and the package it came in to your pharmacy.</item>
                                 <item>Do not remove the orange cap until just before you are ready to inject.</item>
                                 <item>Do not touch the yellow needle cover.</item>
                                 <item>Do not try to put the orange cap back on the pen.</item>
                                 <item>Do not re-use the pen.</item>
                                 <item>Do not freeze or heat up the pen.</item>
                                 <item>Do not expose the pen to direct sunlight.</item>
                                 <item>Do not inject through your clothes.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Keep these instructions for future use.</paragraph>
                  <paragraph>If you have any further questions, ask your healthcare provider or call 1-844-KEVZARA (1-844-538-9272).</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEVZARA pre-filled pen parts</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold">What you will need for your injection:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>An unused KEVZARA 150 mg/1.14 mL pre-filled pen</item>
                     <item>Alcohol wipe</item>
                     <item>Cotton ball or gauze</item>
                     <item>Sharps disposal container. See "<content styleCode="bold">
                           <linkHtml href="#how_dispose">How should I throw away (dispose of) KEVZARA pre-filled pens?</linkHtml>
                        </content>" at the end of this Instructions for Use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step A: Get ready for an injection</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left">
                              <content styleCode="bold">1. Prepare all of the equipment you will need on a clean, flat working surface.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take 1 pen out of the packaging by holding the middle of the pen body. <content styleCode="bold">Do not</content> remove the orange cap until you are ready to inject.</item>
                                 <item>Keep the remaining pen in the carton in the refrigerator.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Look at the label.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check that you have the correct medicine and the correct dose.</item>
                                 <item>Check the expiration date. This is shown on the side of the pen.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the pen if the expiration date has passed.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM3"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Look at the window.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check to see that the liquid in the window is clear and colorless to pale yellow.</item>
                                 <item>You may see air bubbles. This is normal.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject if the liquid is cloudy, discolored or contains particles. Safely throw away (dispose of) the pen in a sharps container and get a new one.</item>
                                 <item>The window is clear when the pen is unused. The window will turn solid yellow after the pen has been used.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use if the window is solid yellow. Safely dispose of the pen in a sharps container and get a new one.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Lay the pen on a flat surface and allow it to warm up at room temperature for at least 60 minutes.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Using the pen at room temperature may make the injection more comfortable.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the pen if it has been out of the refrigerator for more than <content styleCode="bold">14</content> days.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> try to warm the pen in any other way.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Select the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You can inject into your thigh or belly (abdomen), but not the area 2 inches (5 cm) around your belly button (navel).</item>
                                 <item>
                                    <content styleCode="bold">If somebody else gives you the injection, you can also use the outer area of the upper arm</content>.</item>
                                 <item>Change the injection site each time you inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is tender, damaged or has bruises or scars.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Prepare the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Wash your hands.</item>
                                 <item>Clean the skin at the injection site with an alcohol wipe and let it air dry before injecting.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the injection site again before the injection.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step B: Give the injection </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Complete Step B after completing all steps in Step A "Get ready for an injection"</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Twist or pull off the orange cap.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> remove the orange cap until you are ready to inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the yellow needle cover.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the orange cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">
                                 <content styleCode="bold">2. Put the yellow needle cover on your skin at about a 90 degree angle.</content>
                              </content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Make sure you can see the window.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM8"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Press down and hold the pen firmly against your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>There will be a "click" when the injection starts.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM9"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Keep holding the pen firmly against your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The window will start to turn solid yellow.</item>
                                 <item>The injection can take up to 15 seconds.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM10"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. There will be a second click when the injection is complete. Check to see if the entire window has turned solid yellow before you remove the pen.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you do not hear the second click, you should still check to see if the entire window has turned solid yellow.</item>
                                 <item>If the entire window does not turn solid yellow, this means that you may not have received your full dose of medicine. Call your healthcare provider right away.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM11"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Remove the pen from your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>After you remove the pen from your skin, the needle will be covered automatically.</item>
                                 <item>If you see any blood at the injection site, press a cotton ball or gauze on the site.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM12"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">7. Dispose of the pen </content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The KEVZARA pre-filled pen should not be reused.</item>
                                 <item>Put the used pen into your FDA-cleared sharps disposal container or a puncture-resistant container (see "<content styleCode="bold">
                                       <linkHtml href="#how_dispose">How should I throw away (dispose of) KEVZARA pre-filled pens?</linkHtml>
                                    </content>").</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the orange cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM13"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold" ID="how_dispose">How should I throw away (dispose of) KEVZARA pre-filled pens?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put the used pen in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the pen in your household trash.</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Circle">
                           <item>made of a heavy-duty plastic,</item>
                           <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>upright and stable during use,</item>
                           <item>leak-resistant, and</item>
                           <item>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</item>
                     <item>
                        <content styleCode="bold">Do not</content> reuse the pen.</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important:</content> Always keep the sharps disposal container out of the reach of children.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">REGENERON</content>
                        <br/>sanofi</content>
                  </paragraph>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>U.S. License # 1752</paragraph>
                  <paragraph>Marketed by: sanofi-aventis U.S. LLC (Morristown, NJ 07960)<br/>and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology<br/>Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>Issued: May 2025</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a9d27361-ffbd-4560-9faa-19f55c795bcf"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use<br/>KEVZARA<sup>Â®</sup> (KEV-za-ra)<br/>(sarilumab)<br/>injection, for subcutaneous use<br/>Single-dose pre-filled pen (200 mg/1.14 mL)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Important information:</content>
                  </paragraph>
                  <paragraph>KEVZARA is available as a single-dose pre-filled pen (called "pen" in these instructions). The pre-filled pen contains 200 mg of KEVZARA for injection under the skin (subcutaneous injection) 1 time every 2 weeks.</paragraph>
                  <paragraph>Do not try to inject KEVZARA until you have been shown the right way to give the injections by your healthcare provider.</paragraph>
                  <table width="80%">
                     <colgroup>
                        <col width="50%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Lrule Rrule" align="center">Do</th>
                           <th styleCode="Rrule" align="center">Do not</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td styleCode="Lrule Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read all of the instructions carefully before using the pre-filled pen.</item>
                                 <item>Keep unused pens in the original carton and store in the refrigerator between 36Â°F and 46Â°F (2Â°C and 8Â°C).</item>
                                 <item>Keep the carton in an insulated bag with an ice pack when traveling.</item>
                                 <item>Let the pen warm up at room temperature for at least 60 minutes before using.</item>
                                 <item>Use the pen within <content styleCode="bold">14</content> days after taking it out of the refrigerator or insulated bag.</item>
                                 <item>Keep the pen and all medicines out of the reach of children.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not use the pre-filled pen if it has been damaged or the orange cap is missing or not attached. Return the pen and the package it came in to your pharmacy.</item>
                                 <item>Do not remove the orange cap until just before you are ready to inject.</item>
                                 <item>Do not touch the yellow needle cover.</item>
                                 <item>Do not try to put the orange cap back on the pen.</item>
                                 <item>Do not re-use the pen.</item>
                                 <item>Do not freeze or heat up the pen.</item>
                                 <item>Do not expose the pen to direct sunlight.</item>
                                 <item>Do not inject through your clothes.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Keep these instructions for future use.</paragraph>
                  <paragraph>If you have any further questions, ask your healthcare provider or call 1-844-KEVZARA (1-844-538-9272).</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEVZARA pre-filled pen parts</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM14"/>
                  <paragraph>
                     <content styleCode="bold">What you will need for your injection:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>An unused KEVZARA 200 mg/1.14 mL pre-filled pen</item>
                     <item>Alcohol wipe</item>
                     <item>Cotton ball or gauze</item>
                     <item>Sharps disposal container. See "<content styleCode="bold">
                           <linkHtml href="#how_dispose_2">How should I throw away (dispose of) KEVZARA pre-filled pens?</linkHtml>
                        </content>" at the end of this Instructions for Use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step A: Get ready for an injection</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left">
                              <content styleCode="bold">1. Prepare all of the equipment you will need on a clean, flat working surface.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take 1 pen out of the packaging by holding the middle of the pen body. <content styleCode="bold">Do not</content> remove the orange cap until you are ready to inject.</item>
                                 <item>Keep the remaining pen in the carton in the refrigerator.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Look at the label.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check that you have the correct medicine and the correct dose.</item>
                                 <item>Check the expiration date. This is shown on the side of the pen.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the pen if the expiration date has passed.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM15"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Look at the window.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check to see that the liquid in the window is clear and colorless to pale yellow.</item>
                                 <item>You may see air bubbles. This is normal.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject if the liquid is cloudy, discolored or contains particles. Safely throw away (dispose of) the pen in a sharps container and get a new one.</item>
                                 <item>The window is clear when the pen is unused. The window will turn solid yellow after the pen has been used.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use if the window is solid yellow. Safely dispose of the pen in a sharps container and get a new one.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM16"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Lay the pen on a flat surface and allow it to warm up at room temperature for at least 60 minutes.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Using the pen at room temperature may make the injection more comfortable.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the pen if it has been out of the refrigerator for more than <content styleCode="bold">14</content> days.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> try to warm the pen in any other way.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM17"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. Select the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You can inject into your thigh or belly (abdomen), but not the area 2 inches (5 cm) around your belly button (navel).</item>
                                 <item>
                                    <content styleCode="bold">If somebody else gives you the injection, you can also use the outer area of the upper arm</content>.</item>
                                 <item>Change the injection site each time you inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is tender, damaged or has bruises or scars.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM18"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Prepare the injection site.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Wash your hands.</item>
                                 <item>Clean the skin at the injection site with an alcohol wipe and let it air dry before injecting.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the injection site again before the injection</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step B: Give the injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Complete Step B after completing all steps in Step A "Get ready for an injection"</content>
                  </paragraph>
                  <table width="90%">
                     <colgroup>
                        <col width="60%" align="left" valign="top"/>
                        <col width="40%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">1. Twist or pull off the orange cap.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> remove the orange cap until you are ready to inject.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the yellow needle cover.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the orange cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM19"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">2. Put the yellow needle cover on your skin at about a 90 degree angle.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Make sure you can see the window.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM20"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">3. Press down and hold the pen firmly against your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>There will be a "click" when the injection starts.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM21"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">4. Keep holding the pen firmly against your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The window will start to turn solid yellow.</item>
                                 <item>The injection can take up to 15 seconds.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM22"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">5. There will be a second click when the injection is complete. Check to see if the entire window has turned solid yellow before you remove the pen.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you do not hear the second click, you should still check to see if the entire window has turned solid yellow.</item>
                                 <item>If the entire window does not turn solid yellow, this means that you may not have received your full dose of medicine. Call your healthcare provider right away.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM23"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">6. Remove the pen from your skin.</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>After you remove the pen from your skin, the needle will be covered automatically.</item>
                                 <item>If you see any blood at the injection site, press a cotton ball or gauze on the site.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM24"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">7. Dispose of the pen</content>
                           </td>
                           <td align="center"/>
                        </tr>
                        <tr>
                           <td align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The KEVZARA pre-filled pen should not be reused.</item>
                                 <item>Put the used pen into your FDA-cleared sharps disposal container or a puncture resistant container (see "<content styleCode="bold">
                                       <linkHtml href="#how_dispose_2">How should I throw away (dispose of) KEVZARA pre-filled pens?</linkHtml>
                                    </content>").</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the orange cap back on.</item>
                              </list>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM25"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold" ID="how_dispose_2">How should I throw away (dispose of) KEVZARA pre-filled pens?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put the used pen in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the pen in your household trash.</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Circle">
                           <item>made of a heavy-duty plastic,</item>
                           <item>can be closed with a tight-fitting, puncture resistant lid, without sharps being able to come out,</item>
                           <item>upright and stable during use,</item>
                           <item>leak-resistant, and</item>
                           <item>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</item>
                     <item>
                        <content styleCode="bold">Do not</content> reuse the pen.</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important:</content> Always keep the sharps disposal container out of the reach of children.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">REGENERON</content>
                        <br/>sanofi</content>
                  </paragraph>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>U.S. License # 1752</paragraph>
                  <paragraph>Marketed by: sanofi-aventis U.S. LLC (Morristown, NJ 07960)<br/>and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup> is a registered trademark of Sanofi Biotechnology<br/>Â©2025 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>Issued: May 2025</paragraph>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM21">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM22">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM23">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM24">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM25">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a40da7f6-a93e-4fc5-9d16-93bcf166bbc0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Syringe Carton</title>
               <text>
                  <paragraph>NDC 0024-5908-01<br/>Rx Only</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup>
                     <br/>(sarilumab)<br/>injection</paragraph>
                  <paragraph>150 mg/1.14 mL (131.6 mg/mL)<br/>                     2 Single-Dose Pre-filled Syringes<br/>For Subcutaneous Injection Use Only</paragraph>
                  <paragraph>REGENERON <br/>sanofi</paragraph>
                  <paragraph>Store in a refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original<br/>carton to protect from light. Do NOT freeze. Do NOT shake. 						</paragraph>
                  <paragraph>If needed, patients/caregivers may store KEVZARA at room<br/>temperature up to 77Â°F (25Â°C) up to 14 days in the outer carton.<br/>Do not store above 77Â°F (25Â°C). After removal from the<br/>refrigerator, use KEVZARA within 14 days or discard.</paragraph>
                  <paragraph>Date removed from the refrigerator ____/____/____ 						</paragraph>
                  <paragraph>ATTENTION: Enclosed Medication Guide is required for each patient</paragraph>
                  <paragraph>150 mg/1.14 mL</paragraph>
                  <renderMultiMedia referencedObject="MM26"/>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM26">
                     <text>PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Syringe Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="de442319-27c3-46c7-b3a7-c059f4345003"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Syringe Carton</title>
               <text>
                  <paragraph>NDC 0024-5910-01 <br/>Rx Only</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup>
                     <br/>(sarilumab)<br/>injection</paragraph>
                  <paragraph>200 mg/1.14 mL (175.4 mg/mL)<br/>                    2 Single-Dose Pre-filled Syringes<br/>For Subcutaneous Injection Use Only</paragraph>
                  <paragraph>REGENERON<br/>sanofi</paragraph>
                  <paragraph>Store in a refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original<br/>carton to protect from light. Do NOT freeze. Do NOT shake.</paragraph>
                  <paragraph>If needed, patients/caregivers may store KEVZARA at room<br/>temperature up to 77Â°F (25Â°C) up to 14 days in the outer carton.<br/>Do not store above 77Â°F (25Â°C). After removal from the<br/>refrigerator, use KEVZARA within 14 days or discard.</paragraph>
                  <paragraph>Date removed from the refrigerator ____/____/____	</paragraph>
                  <paragraph>ATTENTION: Enclosed Medication Guide is required for each patient</paragraph>
                  <paragraph>200 mg/1.14 mL</paragraph>
                  <renderMultiMedia referencedObject="MM27"/>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM27">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Syringe Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="70b8fba1-5ed5-4841-8a36-31aff67bcc0a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Pen Carton</title>
               <text>
                  <paragraph>NDC 0024-5920-01<br/>Rx Only</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup>
                     <br/>(sarilumab)<br/>injection</paragraph>
                  <paragraph>150 mg/1.14 mL (131.6 mg/mL)<br/>                    2 Single-Dose Pre-filled Pens<br/>For Subcutaneous Injection Use Only</paragraph>
                  <paragraph>REGENERON <br/> sanofi</paragraph>
                  <paragraph>Store in a refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original<br/>carton to protect from light. Do NOT freeze. Do NOT shake.</paragraph>
                  <paragraph>If needed, patients/caregivers may store KEVZARA at room<br/>temperature up to 77Â°F (25Â°C) up to 14 days in the outer carton.<br/>Do not store above 77Â°F (25Â°C). After removal from the<br/>refrigerator, use KEVZARA within 14 days or discard.</paragraph>
                  <paragraph>Date removed from the refrigerator ____/____/____ 						</paragraph>
                  <paragraph>ATTENTION: Enclosed Medication Guide is required for each patient</paragraph>
                  <paragraph>150 mg/1.14 mL 						</paragraph>
                  <renderMultiMedia referencedObject="MM28"/>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM28">
                     <text>PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Pen Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="437c6111-3fbd-4856-951a-c734f9747bbe"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Pen Carton</title>
               <text>
                  <paragraph>NDC 0024-5922-01<br/>Rx Only</paragraph>
                  <paragraph>KEVZARA<sup>Â®</sup>
                     <br/>(sarilumab)<br/>injection</paragraph>
                  <paragraph>200 mg/1.14 mL (175.4 mg/mL)<br/>                     2 Single-Dose Pre-filled Pens<br/>For Subcutaneous Injection Use Only</paragraph>
                  <paragraph>REGENERON <br/>sanofi</paragraph>
                  <paragraph>Store in a refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original<br/>carton to protect from light. Do NOT freeze. Do NOT shake. 						</paragraph>
                  <paragraph>If needed, patients/caregivers may store KEVZARA at room<br/>temperature up to 77Â°F (25Â°C) up to 14 days in the outer carton.<br/>Do not store above 77Â°F (25Â°C). After removal from the<br/>refrigerator, use KEVZARA within 14 days or discard.</paragraph>
                  <paragraph>Date removed from the refrigerator ____/____/____ 						</paragraph>
                  <paragraph>ATTENTION: Enclosed Medication Guide is required for each patient</paragraph>
                  <paragraph>200 mg/1.14 mL 						</paragraph>
                  <renderMultiMedia referencedObject="MM29"/>
               </text>
               <effectiveTime value="20250516"/>
               <component>
                  <observationMedia ID="MM29">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Pen Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="827bc01c-d379-4266-a18c-c7f904b76af3-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>